

Review Article

Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms

Hannu Kankaanranta,^{1,2} Paula Kauppi,³ Leena E. Tuomisto,¹ and Pinja Ilmarinen¹

¹Department of Respiratory Medicine, Seinäjoki Central Hospital, 60220 Seinäjoki, Finland

²Department of Respiratory Medicine, University of Tampere, 33521 Tampere, Finland

³Department of Respiratory Medicine and Allergology, Skin and Allergy Hospital, Helsinki University Hospital and Helsinki University, 00029 Helsinki, Finland

Correspondence should be addressed to Hannu Kankaanranta; hannu.kankaanranta@epshp.fi

Received 11 September 2015; Revised 1 December 2015; Accepted 2 December 2015

Academic Editor: Anshu Agrawal

Copyright © 2016 Hannu Kankaanranta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Asthma is a heterogeneous disease with many phenotypes, and age at disease onset is an important factor in separating the phenotypes. Most studies with asthma have been performed in patients being otherwise healthy. However, in real life, comorbid diseases are very common in adult patients. We review here the emerging comorbid conditions to asthma such as obesity, metabolic syndrome, diabetes mellitus type 2 (DM2), and cardiac and psychiatric diseases. Their role as risk factors for incident asthma and whether they affect clinical asthma are evaluated. Obesity, independently or as a part of metabolic syndrome, DM2, and depression are risk factors for incident asthma. In contrast, the effects of comorbidities on clinical asthma are less well-known and mostly studies are lacking. Cross-sectional studies in obese asthmatics suggest that they may have less well controlled asthma and worse lung function. However, no long-term clinical follow-up studies with these comorbidities and asthma were identified. These emerging comorbidities often occur in the same multimorbid adult patient and may have in common metabolic pathways and inflammatory or other alterations such as early life exposures, systemic inflammation, inflammasome, adipokines, hyperglycemia, hyperinsulinemia, lung mechanics, mitochondrial dysfunction, disturbed nitric oxide metabolism, and leukotrienes.

1. Introduction

Asthma is a common chronic disorder affecting more than 300 million people all over the world with prevalence among adults varying between 0.2 and 21% [1]. Recently, the cluster studies have revealed that asthma is not a single disease but a heterogeneous syndrome manifesting with distinct phenotypes. Age at asthma onset has emerged as a critical factor in distinguishing between phenotypes [2–4]. Patients with early-onset (or childhood-onset) asthma are typically atopic with Th2-predominant inflammation, good responsiveness to glucocorticoids, and good prognosis [5]. In contrast, patients with adult- or late-onset asthma are often nonatopic, are females, have less favourable prognosis, and are more likely to develop persistent airflow limitation [2–4, 6, 7]. Most of asthma is thought to start during childhood. However, this

has recently been challenged by showing that, in United States, adult-onset asthma is the dominant phenotype in women from 40 years of age [8]. Adult-onset asthma and adult-onset phenotypes have been associated with factors such as female sex, obesity, occupational exposure, rhinitis, respiratory infections, smoking, stressful life events, and low level of lung function [2–4]. As recently reviewed in this journal [4] the mechanisms of adult-onset asthma may include several metabolic and inflammatory components that are common to the other diseases such as obesity, metabolic syndrome (MBO), diabetes mellitus type 2 (DM2), cardiovascular diseases (CVD), and psychiatric diseases.

Most clinical trials with asthma have been performed in patients being otherwise healthy. However, in real life, comorbid diseases are very common, especially in adult and/or aging patients. For example, in the US 35% of adult people




FIGURE 1: Emerging comorbidities in asthma.

are obese [9]. In addition, it is rather a rule than an exception that patients not only often present with one comorbid disease but also have several comorbidities, that is, suffering from multimorbidity [10–12].

In early-onset childhood asthma, food allergies, atopic eczema, and allergic rhinitis are common and well-characterized comorbidities [13–16]. Some other comorbid conditions such as gastroesophageal reflux have gained a lot of attention during the years [17–19]. The role of these comorbidities has been thoroughly reviewed elsewhere [13–20]. Chronic obstructive pulmonary disease (COPD) is usually affecting age groups of 40 years and older. Asthma and COPD share many clinical features both being chronic obstructive airway diseases but having variable degrees of reversibility of airway obstruction [21]. The coexistence of asthma and COPD or the recently characterized asthma-COPD overlap syndrome (ACOS) has been reviewed and characterized in treatment guidelines for both asthma and COPD, for example, in Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) reports and in some national guidelines [22–26]. Thus, COPD and ACOS will not be covered by the present review.

In this review, we aim to give the reader an overview of the emerging comorbid conditions to asthma such as obesity, MBO, DM2, CVD, and psychiatric diseases (Figure 1). We focus on asthma in adults and especially on adult-onset asthma if evidence is available. We have five separate aims in this review if such data is available: (A) to characterize the epidemiological evidence how these comorbidities associate with asthma, (B) to describe the role of the comorbidity as a risk factor for incident asthma, (C) the possible role of asthma as a risk factor for the incident comorbidity, (D) the effect of the comorbidity on the clinical outcome of asthma, and (E) to describe the possible common mechanisms that may link asthma and the abovementioned comorbid conditions.

2. Epidemiologic Studies on Comorbidities in Asthma

A Norwegian study on 1 239 533 subjects of 8–29 years old comprised altogether 37 060 asthma patients when asthma was defined as using filled prescriptions on asthma drugs [27]. This study showed higher-than-expected occurrence in all of the diseases studied (attention-deficit hyperactivity disorder (ADHD), epilepsy, migraine, mental illness, cardiovascular, autoimmune, gastroesophageal reflux disease (GERD), allergy, use of antibacterials, and use of antivirals), except diabetes, in patients with asthma. Fifty-nine percent of the asthmatics had one or more of these chronic diseases when the corresponding figure for general population was 18%. In 20–29-year-olds the greatest odds ratios for other diseases in asthmatics were for allergy (OR 4.8 for men, 4.1 for women), GERD (OR 3.2 in men, 3.5 in women), and ADHD (OR 2.3 in men, 2.5 in women). The study population was 8–29 years old but still showed high prevalence of comorbidity.

In a Canadian population-based study (Ontario, Canada; population, 12 million) the burden of asthma-associated comorbidity as measured in rates of hospitalisations, emergency department visits, and ambulatory care claims was evaluated [28]. Asthma comorbidity-associated ambulatory claims, emergency department visits, and hospitalisations were substantial and, in fact, their numbers were much greater than those due to asthma itself [28]. Interestingly, the health burden due to asthma comorbidity appeared substantial regardless of age, gender, socioeconomic status, or living in a rural or urban area [28]. Approximately half of the asthma comorbidity claims were for other respiratory conditions such as upper respiratory tract infection, pneumonia, or allergic rhinitis [28]. In a further study by Gershon and coworkers [29] using the same Ontario data, comorbidity was evaluated as indicated by use of health service in 14 disease categories. In patients with asthma, comorbidity was 46% (0–4 years old), 40% (5–17 years old), 47% (18–44 years old), 49% (45–64 years old), and 22% (65 years old or more) higher than in those without asthma [29]. In all age groups most of the 14 disease categories were more common in patients with asthma. The highest comorbidity (50% or more) was found for respiratory disease other than asthma, psychiatric disorders, metabolic and immunity disorders, and perinatal disorders (0–4 years old). Risk of respiratory disease (other than asthma) was approximately double, and risk of psychiatric disorders and infectious diseases was approximately 33% to 51% higher in individuals with asthma as compared to those without asthma. In the oldest age group, physician claims were approximately twice more common for acute bronchitis and 60% higher for pneumonia in those with asthma as compared to nonasthmatics [29].

The results from Great Britain among incident cases of asthma from primary care were similar showing that patients with asthma ($n = 7931$) have more consultations in all major organ systems than their age- and gender-matched nonasthma controls [30]. The mean age of the patients with asthma in all of the abovementioned studies ranged between 30 and 32 years [28–30] suggesting that a considerable

proportion of the patients represented asthma beginning during childhood. Analysis of aged (>65) patients with asthma suggests that the incidence of comorbidities increases and more closely resembles that of COPD [30]. Thus, it is likely that some comorbidity, such as allergy, may be linked to childhood-onset asthma via common genetic and environmental mechanisms. However, other comorbidities (obesity, diabetes, depression, and anxiety disorders) may be related to asthma symptoms (e.g., sleep disturbance contributing to psychiatric disorders and obesity) or its therapy, for example, glucocorticoids inducing systemic adverse effects [31], diabetes [32], or increased risk for pneumonia [33].

A German telephone interview study of 2,242 current asthmatics (1,429 women) of a total of 43,189 study individuals (18 years or older) evaluated the prevalence of eight different health conditions (diabetes mellitus, hypertension, coronary heart disease, chronic heart failure, stroke, cancer, osteoarthritis, and depression) in patients with asthma as compared with those not having current asthma [34]. All of these eight health conditions were more prevalent in patients with asthma. Almost every fifth of the patients with asthma (17.8%) had at least 3 chronic conditions whereas 8.0% of controls with no current asthma had at least 3 chronic conditions. Interestingly, multimorbidity (i.e., three or more chronic conditions) was associated with increased risk for unscheduled inpatient care (OR 3.4) and for unscheduled outpatient care (OR 2.3) [34].

An analysis of Finnish public sector employees [35] reported that asthma increased the risk of all-cause long-term (sickness absence or disability pension >90 days) work disability (HR 1.8) as compared to controls (no asthma). However, asthma and one chronic comorbid condition increased the risk for long-term all-cause work disability with HR 2.2 and asthma together with two or more chronic conditions increased the risk with HR 4.5 [35]. According to the study results asthma is a minor risk for long-term work disability but asthma with multiple comorbidities is a major risk.

Aging increases morbidity and also multimorbidity in patients with asthma [12]. By no means, multimorbidity is not a unique feature of asthma but rather represents clustering of diseases to certain persons. In fact, out of the 40 conditions studied in large analysis in Scotland [10], there was no condition in which most people had that condition only [12]. Multimorbidity is generally associated with increased risk for mental health disorders [10, 11]. Further, socioeconomic deprivation is associated with multimorbidity suggesting clustering of social, economic, and health problems in certain individuals or in certain areas. Taken together, comorbidity is common in asthma; allergy and obesity are common in younger age groups, whereas obesity, diabetes, GERD, and psychiatric and cardiovascular diseases are found in older age groups. Respiratory infections are found in all age groups.

3. Obesity

3.1. Is Obesity Associated with Asthma? Does Obesity Increase the Risk of Asthma? The studies evaluating the association between obesity and asthma use generally body mass index (BMI) as a tool. A BMI ≥ 25 is considered overweight, while

people with BMI ≥ 30 are classified as obese. BMI is particularly useful as it is standardized, calculated in the same way for both sexes and for adults of all ages [36].

Obesity is a risk factor for asthma, especially among women [37, 38]. A meta-analysis has been performed on the risk [17]. The risk for asthma was 1.20 for overweight and 1.43 for obese men. The corresponding risk estimates for women were 1.25 for overweight and 1.78 for obesity [17]. Also recent large US and Norwegian epidemiological studies report odds ratios ranging from 1.29 [39] to 1.84 [40] for obese males and 1.55 [39] to 1.96 [40] for obese females to have or to develop asthma as compared with their normal weight counterparts. What does this mean in real life? A 25-year follow-up in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort gives us an approximation. Approximately 1 out of 4 obese women followed up from the age of 25 developed asthma during the 25-year follow-up period, whereas approximately 1 out of 7 normal weight women developed asthma [41].

Does increasing obesity increase the risk of asthma? A recent large US epidemiological survey reported an association with the self-reported doctor-diagnosed asthma and the class of obesity. In class I (BMI 30–34.9) obesity OR for asthma was 1.27, in class II (BMI 35–39.9) obesity OR was 1.55, and in class III (BMI ≥ 40) OR was 1.85 indicating a positive association between the degree of obesity and asthma [39]. Similarly, a large Norwegian cohort [40] reported an increased odds ratio for asthma with increasing BMI (per 5 kg/m²) in females (OR 1.32) and in males (OR 1.38). In the US based survey [39] a sex difference was reported by showing that class III obesity is significantly more strongly associated with asthma in women (OR 2.11) than in men (OR 1.40). Similarly, a much less pronounced risk for the development of asthma was seen between normal weight and obese men in the CARDIA study [41]. However, the effect of obesity on the development of asthma may depend on the asthma phenotype. In the long-term follow-up of children hospitalised because of bronchiolitis and many subsequently developing asthma, obesity did not affect the development of asthma in this small cohort [42].

Although cross-sectional studies or follow-up of certain cohorts in adults has demonstrated an increased prevalence of asthma in obese individuals, many of these studies rely on self-reported weight and height. Another possible limitation of these studies is that most rely on a self-reported diagnosis of asthma or symptom-based assessment of asthma rather than on physician records, physiologic evaluation, or response to inhaled therapy. This raises the possibility that the respiratory symptoms are related to the physiologic impairment from obesity rather than to asthma [43]. This is especially important with regard to obesity as obesity increases the possibility to misdiagnosis of asthma [44, 45]. For example, obese subjects who make urgent visits for respiratory symptoms are more likely to receive a misdiagnosis of asthma [44].

Taken together, it appears that obesity is a risk factor for asthma. In contrast, the role of asthma as a risk factor for obesity is much less well-known.

3.2. Obesity and Clinical Asthma. To evaluate the clinical association between asthma and obesity we evaluated studies that directly compared asthma-related endpoints in a cross-sectional or longitudinal study between patients ($n \geq 50$) being normal weight or obese and reporting at least one objective measure of lung function. We identified 7 such studies [44, 46–51] together having 2597 patients with asthma (Table 1(a)). Even though most of these studies suffer from a small number of patients and exclude patients with other comorbidities, they give us an idea what the effect of obesity on asthma may be. All studies were cross-sectional and mostly included all severities of asthma. Most studies excluded smokers and patients with other comorbid states (Table 1(a)). Patients were adults (mean age between 32 and 57), but the age at the onset of the disease was not reported. However, in five studies one can assume that the population contained both patients with childhood- and adult-onset asthma (Table 1(a)). The large analysis of the Severe Asthma Research Program (SARP) [47] evaluated the effect of obesity on asthma parameters separately in early-onset (<12 years) and late-onset (≥ 12 years) asthma. The results are not consistent across the studies (Table 1(b)). However, the results of these studies suggest that obese patients with asthma are older (Table 1(b)). They possibly present with higher age at onset and lower control of asthma, use more steroid courses, experience more hospital admissions and emergency department visits, and have lower lung function although these differences were not reported in all of these studies. Three studies [47–49] primarily recruited patients with severe asthma. The results of these studies are more consistent with regard to oral steroid use during previous year, lung function, and blood eosinophils (Table 1(b)). In support of obese patients presenting with more severe asthma, the association of body mass index and asthma severity was evaluated in the National Asthma Survey in the US [52]. In this large ($n = 3095$) telephone survey obese asthmatics were reported to present with symptoms all the time over the past 30 days (OR 1.7), to have greater than 2 missed work days in the past 12 months (OR 1.4), to use inhaled corticosteroid (OR 1.3), to have GINA medication step 2+ asthma (OR 1.4), to present with classes II–IV persistent asthma (OR 1.4), and to present with severe persistent (class IV) asthma (OR 1.4) [52]. In this cohort, 24% (i.e., almost every fourth) of normal weight patients were classified to have moderate to severe asthma, whereas the corresponding figure among obese patients was 35% [52].

These studies (Tables 1(a) and 1(b)) suggest that there are no differences in inflammatory markers such as blood eosinophils (four studies, $n = 1905$), FENO (three studies), high-resolution computerized tomography scan (one study), and sputum inflammatory cell profiles (one study). In addition, these studies suggest that other comorbidities such as GERD, diabetes mellitus, hypertension, and obstructive sleep apnoea syndrome may be more common in obese asthma patients, although comorbidities were mostly not analyzed (Table 1(b)). Interestingly, two studies [47, 51] reported a reduced probability or tendency of being allergic when being obese and having asthma. This is in agreement with the results obtained from cluster studies that suggest that the

recently identified group of patients with adult-onset obese noneosinophilic asthma phenotype are less allergic/atopic [2–4].

Further, the SARP study found that the effect of obesity is different and more pronounced in early-onset asthma than in late-onset asthma [47]. Thus, asthma beginning in childhood, when being persistent, might be significantly complicated by obesity developing later in life whereas asthma beginning later in adulthood (possibly to the already obese patient) may not be so much more complicated by obesity as obesity may already have been a major driving factor in its appearance. In future, it is of utmost importance to differentiate between patients having asthma and becoming obese later and obese patients with new-onset asthma.

In a small Canadian study [46] (Tables 1(a) and 1(b)), the group of obese asthmatics presented with lower asthma control and had reduced total lung capacity (TLC), expiratory reserve volume (ERV), functional residual capacity (FRC), and residual volume (RV) compared to the normal weight asthmatics [46]. It is well-known that obesity is associated with a reduction in ERV and FRC [53–55], but it still remains contradictory, whether obesity or BMI as such is associated with more severe airway obstruction (FEV_1/FVC) (see Tables 1(a) and 1(b)).

How existing obesity affects the therapy, control, and prognosis of asthma in a prospective setting? We identified one 12-month prospective disease management study that evaluated the impact of obesity in asthma [43]. In children, there was no relationship between BMI and severity of asthma, spirometry findings, quality of life (QoL), or health-care utilization. In adults, there was no relationship between BMI and asthma severity or health care utilization but higher BMI was associated with a significant reduction in QoL and the BMI had an inverse relationship with forced vital capacity (FVC) [43]. The association of obesity with asthma control has been analysed in a large asthma population (Kaiser Permanente Southern California) ($n = 10,233$) [56]. Overweight and obesity were associated with increased relative risk for asthma hospitalizations or emergency department visits (RR 1.4). Obesity was associated with an increased risk for dispensing ≥ 7 short-acting beta-agonist canisters [56]. These analyses suggest that obesity may have different impact on asthma in younger age groups than in adults and that obesity is associated with more asthma symptoms, reduced TLC, and poorer asthma control.

3.3. The Effect of Weight Loss on Asthma and the Effect of Obesity on Pharmacotherapy. Does weight loss improve asthma control? A randomized study by Stenius-Aarniala and coworkers [57] showed that weight loss in 38 obese physician-diagnosed asthmatics is associated with improvements in asthma symptoms, lung function, and health status. This has been confirmed in another study [58] showing that dietary restriction, with or without exercise resulted in a greater benefit in terms of asthma control. Recently, a small controlled study ($n = 16 + 6$) reported that significant weight loss (from 115 kg \rightarrow 98 kg/BMI 45 \rightarrow 36.5) was associated with a significant improvement in PC_{20} (5 \rightarrow 10 mg/mL), FVC% predicted (94 \rightarrow 100), asthma control (ACQ score 1.4 \rightarrow 0.6),

TABLE 1: (a) Background information of clinical studies evaluating the effect of obesity on asthma in adults. (b) Results of clinical studies evaluating the effect of obesity on asthma in adults.

Study	Patient with asthma <i>n</i>	Setting	Country	Asthma criteria	Severity levels included	Smokers included	Other exclusion criteria	Onset of asthma (child/mixed/adult)	Gender (Females%)	Age (mean; years)
Lessard et al., 2008 [46]	88	Cross-sectional	Canada	Confirmed diagnosis based on bronchodilator response or airway responsiveness measurements	All	No	Current smoking or ex-smoker for ≤6 mo	Mixed	68–100	32–44
Pakhale et al., 2010 [44]	346	Cross-sectional	Canada	Sequential lung testing	All	Yes (?)	Asthma ruled out using sequential testing	Mixed	66–73	41–47
Holguin et al., 2011 (SARP early-onset) [47]	543	Cross-sectional	US	A 12% increase in FEV ₁ after a short-acting bronchodilator or a 20% decrease in FEV ₁ after inhalation of methacholine (PC ₂₀ , 25 mg/mL)	All	No	Current smoking or smoking history of 5 years or more	Childhood-onset (<12 years)	49–65	26–35
Holguin et al., 2011 (SARP late-onset) [47]	506	Cross-sectional	US		All	No		Late-onset (12 years or more)	65–74	39–45
Gibson et al., 2013 [48]	666	Cross-sectional	UK	ATS definition of refractory asthma	Severe	Yes (?)	NR	Mixed	65	45
Bruno et al., 2014 [49]	102	Cross-sectional	Italy/France	ATS 1987	Severe	No	Potential confounding diagnosis. Any persistent environmental trigger, COPD, or other differential diagnoses	Mixed	56	57
Ramasamy et al., 2014 [50]	60	Cross-sectional	India	GINA 2009	All	No	Smoker (current or ex), ICS/OCS during previous month, medication for obesity, hypertension, diabetes mellitus/CAD, unable to perform exhaled nitric oxide maneuver	Mixed	50	32–35 (inclusion 20–50 years)
Ciprandi et al., 2014 [51]	286	Cross-sectional	Italy	Documented asthma diagnosis by a specialist based on a history of intermittent wheezing in combination with reversibility to bronchodilators and/or BHR to methacholine	All	No (?)	History of lung disease other than asthma, coronary artery disease, congestive heart failure, cor pulmonale, recent asthma exacerbation or presence of acute (in the last 4 weeks) or chronic upper and/or lower respiratory infections	NR	59	48

NR = not reported, FEV₁ = forced expiratory volume in 1 second, ATS = American Thoracic Society, SARP = the Severe Asthma Research Network, BHR = bronchial hyperresponsiveness, ICS = inhaled corticosteroid, OCS = oral corticosteroid, and CAD = coronary artery disease.

(b)

	Age at onset	Age at duration	Asthma control	Asthma Exacerbations last year	Oral steroids for asthma in the previous year	Hospital admissions last year	Urgent visits to health care due to respiratory symptoms or ED visit preceding year	Hospitalization for asthma ever	Intensive care unit for asthma ever or previous year	Other
Lessard et al., 2008 [46]	↔	ND	↓	ND	ND	ND	ND	ND	ND	TLC, ERV, FRC, and RV lower in obese asthmatics
Pakhale et al., 2010 [44]	↑	↔	ND	ND	ND	↔	↔	ND	ND	Obese individuals who make urgent visits for respiratory symptoms are more likely to receive a misdiagnosis of asthma
Holguin et al., 2011, early-onset [47]	↑	↔	↑	ND	↑	↑	↑	ND	↑	Asthmatic subjects are differentially affected by obesity based on whether they had asthma early (<12 years of age) or later in life
Holguin et al., 2011, late-onset [47]	↑	↔	ND	ND	↔	(↑)	↑	ND	↑	No difference in FENO or sputum eosinophils
Gibeon et al., 2013 [48]	↔	↔	ND	ND	↑	↔	↔	ND	↔	BMI represents per se a factor for the deterioration in disease control in severe asthma
Bruno et al., 2014 [49]	↔	↔	↓	(↑)	↑	ND	ND	↔	↔	No difference in FENO and hsCRP
Ramasamy et al., 2014 [50]	(↑)	↔	ND	ND	ND	ND	ND	ND	ND	No difference in FENO
Ciprandi et al., 2014 [51]	↑	ND	↔	ND	ND	ND	ND	ND	ND	No difference in FENO
Lessard et al., 2008 [46]	↔	↔	ND	↔	↔	↔	ND	ND	ND	Obstructive sleep apnea syndrome
Pakhale et al., 2010 [44]	↓	ND	ND	ND	ND	ND	↑	↑	↑	
Holguin et al., 2011, early-onset [47]	↓	↓	↑	↔	↔	↔	ND	ND	ND	
Holguin et al., 2011, late-onset [47]	↓	↔	↑	↔	↔	(↓)	ND	ND	ND	
Gibeon et al., 2013 [48]	↔	↔	ND	↔	↓	(↓)	↑	ND	ND	
Bruno et al., 2014 [49]	(↓)	(↓)	↑	↔	↔	↔	↔	↑	↔	
Ramasamy et al., 2014 [50]	↔	↔	ND	ND	ND	↔	ND	ND	ND	
Ciprandi et al., 2014 [51]	↓	↓	ND	ND	ND	↓	ND	ND	ND	

ND = not defined; FEV₁ = forced expiratory volume in 1 second. FVC = forced vital capacity. LABA = long-acting 2-agonist. LABA = gastroesophageal reflux disease, TLC = total lung capacity, ERV = expiratory reserve volume, FRC = functional residual capacity, FENO = forced exhaled nitric oxide, hsCRP = high sensitivity C-reactive protein, and ED = emergency department.

and asthma quality of life (AQLQ score 5.6 → 6.1) [59]. In addition, small studies [60–62] have suggested that surgically induced weight reduction is associated with benefits in asthma control, symptoms, hyperreactivity, use of medication, and lung function. Markers of systemic inflammation (hsCRP, adiponectin, and leptin) were reported to be lower after bariatric surgery, whereas only a decrease in mast cells was reported in a group of asthmatics undergoing bariatric surgery [61]. However, the published studies are small (actively treated asthma patients together 27 + 23 + 12) [60–62] and the results suggest that the benefit may diminish over time [60]. Another factor that makes it difficult to assess the effect of weight loss interventions on asthma is that bariatric surgery improves lung function (e.g., FEV₁, FRC, and TLC) in obese patients without asthma [61], suggesting that all improvement is not specific to asthma. A recent self-controlled case series study [63] of obese patients with asthma ($n = 2261$) and undergoing bariatric surgery gives hope that weight loss and bariatric surgery are associated with clear benefits in asthma. Significantly fewer emergency department (ED) visits or hospitalizations for asthma exacerbations occurred within 12 months after bariatric surgery (11% of patients) compared to during the reference period (22% of patients) and the risk remained low in the subsequent period of 13 to 24 months after bariatric surgery (11% of patients) [63]. In practical terms this means that before bariatric surgery 22 patients out of 100 experienced ED visit or hospitalization and after surgery only 11 out of 100 experience such adverse event because of asthma.

Obesity may also affect the response to the pharmacotherapy of asthma. The basic choices of pharmacotherapy [22, 31] of asthma as such are valid also in obese asthmatics. However, the obese asthmatics may be less responsive to standard asthma therapy with ICS as compared with normal weight patients [38] even though the findings are not consistent.

4. Metabolic Syndrome and Asthma

Obesity (high waist circumference) is a major component of metabolic syndrome, a cluster of metabolic components that indicate a significantly increased risk of cardiovascular disease [64]. The other components of metabolic syndrome include elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol, high blood pressure, and elevated glucose or diabetes. In contrast, the association of metabolic syndrome as a syndrome (i.e., not its single components) with asthma has been much less studied [64]. The Norwegian prospective cohort of the Nord-Trøndelag Health Study from 1995 to 2008 [65] reported that metabolic syndrome was a risk factor for incident asthma (OR 1.6). Among components of metabolic syndrome, two remained associated with incident asthma: high waist circumference (OR 1.6) and elevated glucose or diabetes (OR 1.4) [65]. In the CARDIA study abdominal adiposity, elevated blood pressure, and impaired fasting glucose or diabetes were significantly associated with incident asthma. However, after adjustment for BMI their significance was lost suggesting that BMI as such is an independent risk factor for asthma in women [41]. In Korean 40–69-year-old adults, symptoms suggestive of asthma such

as wheezing, resting dyspnea, and postexercise dyspnea were increased in the subjects of the metabolic syndrome group [66]. Abdominal obesity and hypertension were the risk factors for asthma-like symptoms among the components of the metabolic syndrome [66].

The association between obesity and asthma has been already largely studied (see above sections) and the association between DM2 and asthma will be dealt with separately in Section 5. Next, we will shortly review the associations between lipid metabolism and hypertension with asthma. The complex cholesterol and lipoprotein biology [67, 68] are outside the scope of the present review and the oversimplistic “good and bad cholesterol” view does not represent the whole phenomenon. Although several experimental animal studies as well as some epidemiological and clinical studies in children and adolescents [67, 68] suggest an association between cholesterol/lipoproteins and asthma, surprisingly few studies have been published on adults with asthma. Two early studies [69, 70] report conflicting findings in comparing the cholesterol/lipoprotein profiles in adult patients with asthma and healthy controls. A very recent study [71] evaluated the levels of apolipoprotein A-I and large high-density lipoprotein in adult atopic asthma. Serum levels of these positively correlated with FEV₁, whereas serum triglycerides, LDL cholesterol, and apoB were associated with more severe airflow obstruction [71]. Even though the correlations were weak and only atopic asthmatics were included (possibly excluding a larger part of the nonatopic adult-onset asthma population) in this cross-sectional study, it raises an interesting possibility. It suggests that the atherogenic lipid profile is associated with reduced FEV₁ in asthma [68] creating an important link between metabolic syndrome and asthma.

Data from Canadian Community Health Survey with self-reported or self-reported doctor-diagnosed conditions has shown in two different studies that patients with asthma were having approximately 1.4-fold risk for high blood pressure [72, 73]. Similarly, in a sample of Jackson Heart Study, use of medication for hypertension was more common among those African American women reporting current doctor-diagnosed asthma or use of medication to treat asthma [74]. Taking medication for hypertension was a significant risk factor for current asthma in this population [74]. A similar finding has been reported among Arab Americans [75]. Taken together, there is evidence from the epidemiological studies that hypertension and asthma are connected. However, there is scarcity of data from clinical studies whether hypertension complicates asthma or vice versa. A recent study using Kaiser Permanente Southern California registry data showed that hypertension is associated with markers of increased severity of asthma such as use of > 6 canisters of short-acting β_2 -agonist in a 12-month period, oral corticosteroid dispensing, and history of emergency department visits or hospitalizations [76].

Taken together, it still remains unclear whether metabolic syndrome itself is a risk factor for asthma or is the risk factor one (or several) of its components (obesity?). In addition, the impact of MBO or its therapy on clinical asthma remains mostly unknown [64].

5. Diabetes Mellitus and Asthma

Type I diabetes has been suggested to be an autoimmune disease due to environmental factors, possibly viruses, whereas type 2 diabetes mellitus has been connected with obesity, insulin resistance, and systemic inflammation [77–80].

An analysis of the large Kaiser Permanente Medical Care program has evaluated the risk of asthma among those with diabetes. In adults (aged ≥ 18 years) with no diabetes age- and sex-adjusted incidence of asthma was 0.16 per 1,000 person-years and in those with diabetes the corresponding figure was 0.41 indicating a higher risk for incident asthma [78]. This association between increased prevalence of asthma in patients with DM2 has also been confirmed in a large Danish twin study [79] and in hospitalized patients [80]. The proposed mechanisms how asthma could increase the risk for DM2 include genetic pleiotropy, lung-related inflammatory cytokines and their effects on insulin sensitivity, direct effects of hypoxia on glucose metabolism, and adverse early-life exposures and their effects on organ development [81]. In addition, severe asthma is treated with repeated courses or persistent per oral glucocorticoids that may increase the risk of type 2 diabetes [32] even though this has not been confirmed in other studies [82, 83]. Risk estimates for diabetes in patients with asthma have varied from 1.3 to 2.1 [81, 84, 85]. Asthma-diabetes association appeared stronger for adult-versus child-diagnosed asthma cases, and for participants who were obese compared to those who were nonobese [81]. The current data suggests that a connection between asthma and DM2 diabetes exists and suggests that both diseases are able to increase the risk of the other disease. In contrast, the effect of DM2 on asthma outcome remains unknown.

6. Cardiovascular Diseases and Asthma

Previously connection of asthma and arteriosclerosis has been evaluated in studies of asthma mortality or in studies among elderly patients with asthma. Patients with severe asthma have been reported to have a higher mortality from ischemic heart disease especially among women [86]. However, such a connection between these diseases has not been found in elderly asthma patients [69, 87].

6.1. Are Asthma and Cardiovascular Diseases Associated? A large cross-sectional study ($n = 16,943$) looked for the associations between adult-onset asthma and CVDs including stroke, congestive heart failure, and coronary heart disease [88]. Adult-onset asthma (age of onset ≥ 18 years) was found to have a significant association with total CVD (OR 2.1). Only coronary heart disease (CHD) was significantly associated with adult-onset asthma (OR 2.3). In gender stratified analyses, only females with adult-onset asthma showed an increase in the odds for total CVD (OR 2.4) and CHD (OR 2.9). In contrast to expectations, overweight (BMI 25–30) females with adult-onset asthma had stronger association with CVD than those having adult-onset asthma and being obese (BMI > 30) [88]. The limitations of the study were the cross-sectional setting and definition of smoking history (nonsmokers or current smokers) thus making exclusion of COPD impossible [88].

6.2. Does Asthma Increase the Risk of Cardiovascular Diseases?

Over the past decade large cohort studies have been published to assess the risk of cardiovascular events as asthma comorbidities. In a large cohort study of health insurance database ($n = 151,620$) connection of asthma and combined nonfatal or fatal CHD was assessed [89]. Patients (age ≥ 18 years) with self-reported physician-diagnosed asthma or hospitalization due to asthma were followed for 27 years. In women, the age-adjusted CHD rate was higher in those with asthma than in those without asthma with a HR of 1.2. Asthma was associated with the risk of developing CHD in both younger (< 50 years) (HR 1.2) and older (≥ 50 years) women (HR 1.2). Asthma among women became significantly associated with CHD events already after 10 years of follow-up (HR 1.2). This suggests that women might have a greater biological susceptibility to the inflammatory asthma milieu or to the cardiotoxic or metabolic effects of asthma medications [89].

Several studies of the Arteriosclerosis Risk in Communities (ARIC) cohort have been published concerning asthma and CVDs as comorbidity [90]. In a prospective study with 14 years of follow-up asthma was modestly associated with an increased incidence of stroke [91]. In a further study of the same cohort [92] evaluating the relationship between asthma and carotid artery intima-media thickness (IMT) also the age at asthma onset was taken into consideration [92]. The weighted mean for wall IMT thickness for women with history of adult-onset asthma (≥ 21 years) was significantly greater than that of women without asthma. In contrast, IMT in women with a history of childhood-onset (< 21 years) asthma did not differ substantially from nonasthmatic women. Third study of the ARIC cohort [93] evaluated incidence of CHD and stroke among asthma subtypes (asthma onset $<$ or ≥ 21 years). Women, but not men, with adult-onset asthma were found to have a 2-fold increased rate of CHD compared to their nonasthmatic counterparts.

Iribarren and coworkers [94] followed two matched adult cohorts, the other with asthma and a parallel asthma-free cohort. Both cohorts were followed up for 12 years for incident nonfatal or fatal CVD and all-cause mortality. Asthma was associated with a 1.4-fold increased risk of coronary heart disease, a 1.2-fold risk of cerebrovascular disease, a 2.1-fold risk of heart failure, and a 3.3-fold risk for all-cause mortality. Similarly to that found in the ARIC cohort [92, 93] stronger associations were noted among women, but there was no data on asthma onset or asthma severity [94]. Among patients with asthma, 84% used one or more asthma medication and particularly those using oral corticosteroids alone or in any combination with asthma medications were at enhanced risk for developing CVD, which may reflect that they were having severe asthma [94]. There remains a possibility that the medication used may increase the risk of CVD as especially β_2 agonists have many adverse cardiovascular side-effects and continuous use of glucocorticoids may have many metabolic disadvantages [89, 94].

Recently, a long-term (10 years) prospective study reported an association of persistent asthma and CVD events (coronary death, myocardial infarction, angina, stroke, and CVD death) [95]. All participants ($n = 6792$) were free of CVD at baseline. Self-reported asthma cases ($n = 667$) were

classified as persistent (daily use of controller medication such as ICS, LTRA, and OS) in 77% and intermittent (without controller medication) in 23% of patients. After a decade of follow-up patients with persistent asthma had a 1.6–1.7-fold higher risk of CVD events than nonasthmatics. In addition, markers of systemic inflammation (IL-6, CRP, alfa-dimer, and fibrinogen) were the highest in patients with permanent asthma even though patients were using modern controller asthma medication. Use of controller medication did not abolish the increased risk of CVD events [95].

Current and former smoking are one of the main risk factors for both asthma and cardiovascular diseases. Recently published report [96] from the Copenhagen General Population study cohort ($n = 94,079$) assessed prospectively the risk of asthma and CVD including ischemic heart disease, myocardial infarction, and ischemic stroke among smokers and nonsmokers. Six percent ($n = 5691$) had self-reported asthma, 40% were never smokers, 43% former smokers, and 16% current smokers. Mean follow-up time of the study patients (age 20–100 years) was 4.5 years. Hazard ratios among individuals with asthma compared to never smokers without asthma for ischemic heart disease were 1.5 in former smokers and 2.0 in current smokers. The respective corresponding values were 1.7 and 3.2 for myocardial infarction and 1.2 (n.s.) and 3.0 for ischemic stroke. In contrast to previous studies the increased risk for cardiovascular comorbidities in this cohort study was restricted only to smokers with asthma [96]. Unfortunately data on the age at asthma onset was not available as in other cohorts the increased risk of CVD was seen mostly only in women with adult-onset asthma. In addition, the follow-up time (4.5 years) is relatively short for the never smoker asthma group as they were women with a mean age of 53. The risk of myocardial infarction in smoking persons increases more early but in never smokers (especially women) it clearly increases only after the age of 60 [97]. In most asthma comorbidity studies confounding effect of smoking has been taken into account. Usually patients have been divided into groups of current, ever, and never smokers. In some studies data on pack-years is available. However, more detailed information like duration, intensity, and type of smoking as well as age of smoking onset and second hand smoking should be part of the multivariate models especially in studies concerning asthma and the risk of cardiovascular diseases [98].

These cross-sectional and cohort studies with large populations have shown that asthma patients and especially a subgroup of adult-onset asthma women are at increased risk of arteriosclerosis. In future, it would be important to know whether totally controlled asthma would reduce the risk of cardiovascular comorbidities. The role of contemporary asthma medication to prevent or to enhance incidence of cardiovascular diseases also remains obscure. Furthermore, we lack knowledge of how different CVDs affect asthma outcome and whether CVDs are of importance in making decisions on how to modify treatment of asthma.

7. Mental Disorders, Suicide, and Asthma

The association between asthma and psychological factors has been recognized for centuries [99]. Psychosocial factors

have long been suspected to influence the onset and course of asthma. These effects may be mediated via direct influences such as influences on the pulmonary system, autonomic and endocrine regulation, and inflammatory and immune process (see later in this paper and [100]). In addition, psychosocial factors can influence asthma via multiple indirect pathways such as medication adherence, perception of airway obstruction (either overperception or underperception), illness beliefs, or general health behavior [100].

A considerable number of studies have suggested that there is an association between some mental disorders and asthma, especially severe asthma [99–101]. Studies conducted among clinical and general practice samples have found higher than expected rates of anxiety disorders (particularly panic disorder) and of depression among adult patients with asthma [99]. However, the published results have not always been consistent and methodological problems (e.g., not using DSM-based diagnostics and variability in the assessment of asthma) make it difficult to draw clear conclusions [99, 100].

7.1. Is There Association between Asthma and Mental Disorders? The World Mental Health Survey performed in 17 countries ($n = 85,088$) using general population sample reports that an adult with asthma has an increased risk for depressive disorders (OR 1.6) and anxiety disorder (OR 1.5) as compared with persons not having asthma [101]. A meta-analysis estimating the prevalence of anxiety disorders in asthma reported that the average prevalence of any anxiety disorder among adults with asthma was 34% [102]. More specifically, the prevalence of panic attacks (25%), panic disorder (12%), agoraphobia (12%), and generalized anxiety disorder (9%) was higher among adults with asthma than in the general population [102]. A recent meta-analysis has evaluated the association between asthma and depression [103]. Patients with depression had increased risk for having asthma (OR 3.2) as compared with those not having depression and patients with asthma had an increased risk for having depression (OR 1.5) as compared with those not having asthma [103]. A similar association has been reported from Spanish National Health Survey [104] reporting that asthmatic patients suffer more often from anxiety (9.7%) and depression (9%) than persons not having asthma (6.6% and 5.5% for anxiety and depression, resp.). Having asthma increased the probability of suffering from anxiety (OR 1.3) and depression (OR 1.4). Among asthmatics factors associated with suffering from anxiety were older age, concomitant comorbidities, and visits to GP practices in the last 4 weeks, whereas factors associated with depression were female sex, older age, worse self-related health, concomitant comorbidities, abstemious individuals, and the need for attendance on emergency room in the last year [104]. A similar association has been reported also from Germany reporting that lifetime severe asthma was significantly associated with an increased risk for a number of anxiety disorders (any anxiety disorder, panic disorder, panic attacks, social phobia, specific phobia, and generalized anxiety disorder), bipolar disorder, and any severe mental disorder [105]. Lifetime nonsevere asthma was significantly associated with having any anxiety disorder, not specified anxiety disorder, and with any somatoform disorder [105].

It appears that the association between anxiety/depression and asthma is not limited to Western countries as similar association has been reported from Chinese population [106] and from an analysis of self-reported data from most of the evaluated 54 countries [107]. In addition, the association between asthma and/or atopic diseases with anxiety and depression is not limited to adults only but has been reported also in children [108] and adolescents [109].

In a Norwegian population-based survey [110] cases with a personality problem evaluated using the Iowa Personality Disorder Screen more frequently reported asthma along with other chronic conditions such as persistent muscular pain, fibromyalgia, and alcohol problems. Asthma (ever suffered from asthma) was found to be of borderline significance in influencing the prevalence of personality problems [110]. As patients with personality problems have increased somatic morbidity and primary health care utilization these results raise another possible cluster of diseases, namely, association between asthma and personality problems and persistent musculoskeletal pain and fibromyalgia that are generally considered as “noninflammatory” diseases. A possible link between these conditions and asthma may be the increased use of nonprescribed analgesics by these patients.

Suicide is a major public health issue worldwide often associated with mental illnesses. Asthma can have a significant effect on quality of life, and consequences include sleeplessness, daytime fatigue, reduced activity levels, school and work absenteeism, and mental health problems [111]. Thus, it can be hypothesized that asthma could be associated with suicide-related behavior. A recent review [111] collected the available observational studies between asthma and suicide-related behavior (ideation, attempts, and completion). The evidence from six different observational studies support an association between asthma and suicide-related behavior the risk being 1.4–3.5 times higher in patients with asthma as compared with nonasthmatic counterparts [111].

7.2. Does Asthma Predispose to Mental Disorders? The only study identified to address this connection evaluated whether asthma predisposes to mental disorders in a longitudinal setting in a Danish birth cohort (children born between 1977 and 1992 and followed up from the age of 15 until year 2008) when they were evaluated for the presence of schizophrenia [112]. Asthma was associated with an increased risk (RR 1.6) for developing schizophrenia and the risk was confirmed in a case/sibling study [112]. Due to its setting (free of charge Danish public health care), this study most probably avoids most of the biases usually related to studies on mental disorders. However, it evaluates only hospital discharge and outpatient data and may thus exclude the less severe cases of asthma.

7.3. Do Mental Disorders Predispose to Asthma? As a part of World Mental Health surveys ($n = 18,303$) the association between childhood adversities (physical abuse, sexual abuse, neglect, parental death, parents divorce, another parental loss, parental mental disorder, parental substance use, parental criminal behavior, family violence, and family economic adversity) and early-onset depressive and anxiety disorders

and adult-onset asthma has been evaluated [113]. Childhood adversities predicted adult-onset asthma with risk increasing with the number of adversities experienced (HRs 1.5–1.7). However, also early-onset depressive and anxiety disorders independently predicted adult-onset asthma (HRs 1.7–2.1). This suggests that mental disorder-asthma relationship is independent and not a function of a shared background of childhood adversity [113]. Data collected from face-to-face household surveys in community-dwelling adults ($n = 52,095$) from 19 countries evaluated the lifetime prevalence and age at onset of 16 DSM-IV mental disorders as well as self-reported physician diagnosis of asthma and age at onset. After adjustment for comorbid mental disorders several mental disorders were associated with subsequent adult asthma onset: bipolar disorder (OR 1.8), panic (OR 1.4), generalized anxiety (OR 1.3), specific phobia (OR 1.3), posttraumatic stress (OR 1.5), binge eating (OR 1.8), and alcohol abuse (OR 1.5). Mental comorbidity linearly increased the association with adult asthma. The association with subsequent asthma was stronger for mental disorders with early onset (before age of 21) [114]. The major biases in these multinational analyses may relate to cultural differences in the diagnostic accuracy when questions on doctor-diagnosed asthma are presented or the World Mental Health survey tools are used.

7.4. Do the Mental Disorders Affect Clinical Asthma? Anxiety and other psychiatric morbidities are often advised to be considered in differential diagnostic and when estimating treatment options in severe asthma or asthma not responding to treatment. Despite this common advice there exist relatively few studies that have directly evaluated how the mental disorders affect clinical asthma. The effects of comorbid mental disorders on health care service use and psychosocial factors in asthma have been reviewed recently [100, 115]. In this review we included only studies more recently published or most relevant to adult asthma. A clinical sample of adult Canadian patients with asthma ($n = 504$, not specifically adult-onset asthma) was subjected to evaluation of the presence of depressive and/or anxiety disorders by using the Primary Care Evaluation of Mental Disorders Interview [116]. Almost one-third of the patients fulfilled the diagnostic criteria for either condition (8% were depressive only and 12% had anxiety only) or both (11%) of these disorders. Depressive disorder had an independent worsening effect on asthma control, whereas both depressive and anxiety disorder independently impaired asthma-related quality of life [116]. In contrast, there were no significant differences in other asthma-related endpoints (lung function, severity, atopy, emergency department visits, hospitalization in the last year, or asthma medication) [116]. The same research group has more recently analysed the impact of generalized anxiety disorder on asthma morbidity in a sample of adult patients with confirmed asthma ($n = 749$, not specifically adult-onset asthma) [107]. Generalized anxiety disorder affected 4% of the patients and impaired asthma control and asthma-related quality of life, increased bronchodilator use, and was associated with worse asthma self-efficacy [117]. However, the comorbid major depressive disorder and low asthma self-efficacy may account for many of these associations [117]. In

contrast, there was no association between generalized anxiety disorder and emergency visits or hospitalizations [117]. This is in line with a systematic review made on psychiatric morbidity and asthma and health care costs [115] in which mood disorders (depression), posttraumatic stress disorder, and not specified mental disorder were found to increase the risk for emergency department visits (ORs 2.6, 5.2, and 4.6, resp.). In contrast, results for anxiety/panic disorder were not consistent between studies [115], although they suggest a trend towards increased emergency department visits. Similarly, increased rate of general practitioner visits was found with patients having depression, posttraumatic stress disorder, and not specified mental disorder but the results with anxiety/panic disorder were not consistent [115]. A recent analysis evaluated the effect of panic disorder and panic-anxiety on asthma control, health service use, and quality of life in adult patients with asthma ($n = 643$, not specifically adult-onset asthma) during a 4-year follow-up [118]. Panic disorder and anxiety sensitivity index (ASI) scores predicted worse follow-up ACQ total scores but not AQLQ scores [118]. ASI scores also predicted greater nocturnal and waking symptoms, activity limitations, and bronchodilator use. In contrast, neither panic disorder nor ASI scores were associated with hospitalisation, although ASI score was marginally associated with an increased risk of emergency department visits (RR 1.023) [118]. Among severe asthmatics the presence of a psychiatric disorder has been reported to increase the risk for frequent visits to GP (OR 5.9), frequent emergency visits (OR 5.3), frequent exacerbations (OR 12.4), and frequent hospitalizations (OR 4.8) even though these patients do not differ from those not presenting with psychiatric disorder in demographic or objective disease characteristics [119]. There exists a possibility that the deleterious effects of mood or anxiety disorders on asthma control might be mediated via behavioural effects such as tobacco smoking. A recent study [120] evaluated this and found that current smoking, having an anxiety disorder, and having a mood disorder are independently associated with poorer asthma control. Recently, it has been proposed that the depressive symptoms mediate the relationship between BMI and worse asthma control [121] although this has not been confirmed in another study [122].

Mental disorders are often associated with increased rate of work absence. The results of two separate studies [35, 123] suggest an increased rate of work absence in asthma with comorbid depression (ORs 3.6–4.0). In a Finnish analysis of public sector employees [35], the risk was especially high for permanent work disability (HR 6.8) [35].

There remain a number of possible problems with the studies evaluating the effects of comorbid mental disorders on the outcome of clinical asthma. Firstly, many studies are cross-sectional and long-term follow-up studies are lacking. Secondly, many studies rely on self-reported data rather than clinical assessment or collection of clinically proven events from patient records. Thirdly, the patient population in clinical studies often represents tertiary care; that is, the group of patients with asthma is highly selected. Fourthly, smoking and differential diagnostics towards COPD are not taken into account. However, there exists enough evidence to

suggest that psychiatric comorbidities associate with asthma and may negatively affect its outcome. Thus, long-term follow-up studies evaluating the effects of different mental comorbidities on asthma outcome are needed.

8. Mechanisms Linking Asthma with Its Comorbidities

Considering the high coexistence of obesity, metabolic syndrome, type 2 diabetes, and depression with asthma, it is not surprising to find many overlapping pathways in their possible pathogenetic mechanisms. Other than traditional, Th2-related mechanisms are likely to explain the coexistence, because the current reports suggest no clear association between BMI and eosinophilic airway inflammation in asthma. To briefly review studies concerning airway inflammation in obese asthma, no difference was found in airway inflammation in morbidly obese subjects with or without asthma [124]. Increase in bronchial submucosal eosinophils, even though not in blood or sputum eosinophils, was reported in severe obese asthmatics when compared to leaner asthmatics [125]. Inverse or no relationship between BMI and sputum/blood eosinophilia or FeNO has commonly been described in patients with asthma. Furthermore, no consistent results exist on predominating neutrophilic airway inflammation either [46, 126–128]. Thereby, it is likely that the increased symptoms in obese patients with asthma are not explained by increased airway inflammation. Next, we will continue by describing the mechanisms that link the pathogenesis of comorbid conditions such as obesity, type 2 diabetes, cardiovascular diseases, and depression with asthma. Due to high degree of overlapping mechanisms, the section is sectioned by mechanisms instead of separate comorbid conditions.

8.1. Early Life Exposures. Early life exposures such as maternal diet, maternal smoking, air pollution, and pregnancy complications affect metabolic health of the offspring and the risk of developing chronic disease later in life. For example, maternal obesity has been associated with both increased risk of insulin resistance and asthma of the offspring during childhood [129, 130]. Also low birthweight has been associated with increased risk of having asthma, hypertension, diabetes, or heart diseases by age of 50 years [131]. These risks may be mediated by structural, metabolic, or epigenetic changes that occur in foetus in response to adverse environment in utero [132]. For example, epigenetic modifications such as DNA or histone methylation and histone acetylation in foetal genes important for lipid or carbohydrate metabolism or immune system are likely mechanisms involved in explaining later risk and higher occurrence of many metabolic and other chronic diseases [133].

Severe early life stress has been associated with depression as well as asthma later in life [134–137]. To explain this association, severe childhood stress was shown to predispose to persistently high inflammatory status of the body (CRP and IL-6) lasting to adulthood. In subjects with severe childhood adverse events the systemic levels of inflammatory cytokines were also raised higher in response to an adverse

event in adulthood when compared to those without childhood adverse events [134, 135]. The persistently activated inflammatory pathways may increase susceptibility to other chronic inflammatory diseases.

8.2. Systemic Inflammation. Systemic inflammation is a phenomenon common for obesity, diabetes mellitus, depression, and at least certain phenotypes of asthma constituting a possible link between these disorders [103, 138]. Systemic inflammation is generated by adipose tissue at the obese state or can be developed, for example, in response to severe social stress. It is characterized by increased levels of inflammatory markers such as C-reactive protein (CRP), interleukin- (IL-) 6, IL-1 β , tumor necrosis factor- (TNF-) α , and leptin. Elevated IL-6, CRP, and soluble CD163 (macrophage activation marker) have been associated with reduced lung function (especially in severe asthma) and neutrophilic airway inflammation [138–140]. TNF- α has also been shown to enhance eosinophil survival [141]. IL-6 possesses wide effects on innate immune system and has been proposed to play an active role in asthma pathogenesis. IL-6 may affect asthma development, for example, by stimulating neutrophil recruitment and T helper cell differentiation into Th2 or Th17 cells (the latter in the presence of TGF- β) or by stimulating IL-13 production by T helper cells [142, 143]. Th17 cells are involved in neutrophil recruitment; they are steroid-resistant (in contrast to, e.g., Th2 cells) and considered to be significant players in severe neutrophilic asthma. Recently, higher amount of dual-positive Th2/Th17 cells was found from BAL of patients with refractory asthma when compared to disease control subjects [144]. IL-6 and IL-1 β are cytokines able to induce differentiation of Th2 cells into Th2/Th17 cells and are likely involved. Amount of Th2/Th17 cells as well as IL-17 levels in these patients positively correlated with airway hyperreactivity and eosinophil counts and negatively correlated with FEV₁ suggesting that Th2/Th17 cells associate with severe asthma. Moreover, dual-positive Th2/Th17 cells were resistant to proapoptotic effects of glucocorticoids [144]. Given that obese patients with asthma are less sensitive to treatment with steroids [38] either Th2/Th17 or Th17 induction by IL-6 may play a significant role in the disease process. Because obesity stimulates systemic inflammation, and cytokines of systemic inflammation skew Th cells into Th17, elevated levels of Th17 cells and elevated production of IL-17 would also be expected in obese subjects and patients with type 2 diabetes. Indeed, this was shown in peripheral blood cells from patients with type 2 diabetes [145]. Moreover, 3–10-fold increases in Th17 cells were demonstrated in adipose tissue from obese patients with insulin resistance, when compared to obese insulin-sensitive or lean patients [146]. Taken together, Th17 cells may be induced in the milieu of systemic inflammation and play a role in pathogenesis of both insulin resistance and asthma. Th17 cells have also been shown to increase with age in healthy humans [147], and an experimental study suggested that development of Th2/Th17 milieu following allergic response would be related to older age [147, 148].

A recent study on gene expression of blood CD4⁺ T cells from patients with depression and asthma showed

that the main active pathways in depressive asthma are those related to acute phase protein signalling (such as IL-6 and CRP signalling) [149]. Chronic stress may lead to dysregulation of hypothalamic-pituitary-adrenal (HPA) axis, long-term increase in the levels of cortisol, glucocorticoid resistance, and systemic inflammation. Cytokines elevated during systemic inflammation are able to generate symptoms such as fatigue and loss of appetite that overlap with symptoms of depression [137, 150]. Moreover, reduced serotonin neurotransmission is present in depression and inflammatory cytokines elevate enzyme indoleamine-2,3-dioxygenase (IDO), which degrades the most important precursor of serotonin, tryptophan [151].

8.3. Inflammasome. Nod-like receptor protein 3 (NLRP3) inflammasome is a multiprotein complex at the interface of metabolism and inflammation and involved in the development of systemic inflammation. Its activation is a two-step process leading to release of IL-1 β and IL-18, mainly in the cells of innate immunity. The interest lies in its ability to be activated by wide array of dangerous substances ranging from pathogens to metabolic compounds (elevated extracellular glucose, amyloid- β peptide, and oxidized low-density lipoprotein (LDL)), extracellular acidosis, and number of environmental irritants [152]. Also psychological stressors have been shown to elevate IL-1 β and may therefore activate inflammasome, even though direct activation mechanisms have not been demonstrated [153]. The precise mechanisms of NLRP3 inflammasome activation by these various factors are largely unknown. Extensive literature supports the role of ROS and mitochondrial dysfunction in inflammasome activation, both being common in obesity, diabetes, and asthma [152, 154]. Studies with knock-out mice have suggested that under normal circumstances IL-1 β is important for maintenance of adipose tissue homeostasis and has partially overlapping functions with IL-6. However, during inflammatory conditions and chronic stimulation, it drives obesity-related disease progression, for example, by interfering with insulin signalling in adipose tissue and liver. Interestingly, in mice IL-1 β and TNF- α also upregulated serotonin transporter (SERT) gene that is central in inducing despair-like behaviour by uptake of serotonin to the presynaptic neuron [155, 156]. By this mechanism inflammasome and IL-1 β could contribute to depression. Moreover, NLRP3 inflammasome has been found to be involved in ageing-related inflammation and cognitive decline [152].

Finally, development of airway hyperresponsiveness in response to high-fat diet in mice was shown to be dependent on NLRP3 inflammasome-mediated production of IL-1 β and IL-17 [157]. IL-1 β expanded IL-17A-producing type 3 innate lymphoid cells (ILC3s) in the lungs. Also patients with severe asthma were shown to have higher numbers of IL-17A-positive ILC3-like cells in BAL when compared to healthy subjects or patients with mild asthma [157]. Altogether, existence of wide array of activators of NLRP3 inflammasome suggests that it may be involved in translating metabolic or inflammatory danger signals into metabolic diseases, airway hyperresponsiveness, and even depression.

8.4. Adipokines. Adipokines have been widely studied in the context of finding the link between obesity and asthma. Adipokines are group of cytokines produced by adipose tissue and contain mediators with proinflammatory (e.g., leptin and resistin) and anti-inflammatory (e.g., adiponectin) functions. Serum levels of leptin increase with increasing BMI [158, 159] and are higher in females [160]. Both clinical and experimental evidence suggest that leptin functions by augmenting airway hyperresponsiveness but not by affecting inflammation [161–163]. In obese patients with adult-onset asthma, markers of metabolic inflammation, macrophage number, and leptin levels were increased in visceral fat when compared to obese controls and airway reactivity was significantly correlated to visceral fat leptin expression [161]. In nonobese women with adult-onset asthma, leptin correlated negatively with lung function and positively with asthma symptom score, after adjusting for BMI [164]. How metabolic inflammation in visceral fat and the mediators involved translates into airway hyperresponsiveness remains unknown. Adipokine receptors are expressed in the airway epithelium and smooth muscle cells and in eosinophils suggesting that there may be direct effects on the structural and inflammatory cells of the airways [161, 165, 166]. In eosinophils, leptin has been shown to promote survival [167, 168].

Adiponectin is an adipokine with insulin-sensitizing and anti-inflammatory effects, and low level of adiponectin has been associated with both incident asthma and metabolic disorders, even though the association has not been consistent [169, 170]. Currently, the primary target cells that are important for the beneficial anti-inflammatory effects of adiponectin are unknown. Adiponectin circulates in the blood only in multimeric forms with low, medium, or high molecular weights and their distribution differs in men and women [171]. Indeed, quite differential associations have been found between adiponectin levels and metabolic diseases or asthma in men and women, and the mechanisms may be largely gender-specific [172, 173]. Even though adiponectin has been demonstrated to suppress activation of many proinflammatory molecules in adipocytes and macrophages in previous studies [174, 175], very recently the effect of adiponectin on inflammation was shown to be dependent on macrophage phenotype. In classically activated mouse M1 macrophages adiponectin increased levels of proinflammatory cytokines IL-6, TNF- α , and IL-12 but in alternatively activated M2 macrophages it enhanced production of anti-inflammatory IL-10 [176]. Even though M2 macrophages are prevalent in traditional allergic asthma, obesity is associated with increase in M1 macrophages at least in adipose tissue [177], and thereby adiponectin might actually exert proinflammatory effects in obesity-associated conditions. More studies are needed to clarify the issue.

8.5. Hyperglycemia and Hyperinsulinemia. Studies have shown 3–10% lower lung function (more consistently FVC than FEV₁) in adults with diabetes (without asthma) when compared to adults without diabetes and the association was independent from obesity or smoking. In longitudinal studies, reduced baseline lung function (mostly FVC) was also shown to predict incident diabetes [178]. Hyperglycemia

and hyperinsulinemia follow insulin resistance and are both prevalent in metabolic syndrome and, in untreated type 2 diabetes, hyperinsulinemia is also present in treated type 2 diabetes. The effects of high glucose or insulin on the lungs have received interest in attempts trying to find an explanation to the association between diabetes and reduced lung function.

Experimental studies and development of inhalation formula of insulin have provided some interesting insights to the direct effects of glucose and insulin on the lungs. In experimental studies, insulin has been shown to contribute to formation of hypercontractile airway smooth muscle cells by promoting expression of laminin [179]. To support this, inhalation of insulin by diabetic patients resulted in cough and decrease in FEV₁ [180]. Insulin also promotes fibroblast proliferation and differentiation resulting in collagen deposition, thereby contributing to airway remodelling [181, 182]. However, infusion of insulin into obese subjects led to anti-inflammatory effects in their peripheral blood mononuclear cells. Insulin reduced short-term activation of NF- κ B and expression of many inflammatory mediators (IL-4, ADAM-33, LIGHT, and LTBR) related to asthma in these cells [183, 184]. In experimental studies, insulin has also contributed to Th2 response and induced mast cell survival and degranulation [181, 182]. *In vitro*, high glucose concentration was shown to enhance responsiveness of airway smooth muscle cells to contractile agents and to enhance intracellular calcium release [185]. Altogether, chronically high insulin or glucose levels in the lungs may promote airway hyperresponsiveness and airway remodelling and thereby contribute to reduced lung function or incident asthma in patients with diabetes. Other mechanisms proposing to explain the reduced lung function in patients with diabetes are microangiopathy of the alveolar capillaries and pulmonary arterioles, as well as autonomic neuropathy [178, 186].

Hyperglycemic condition is common in patients with acute asthma exacerbations, and generally disturbance in glucose metabolism has been described in patients with asthma, even in the absence of any diabetic risk factors [187, 188]. Hyperglycemic condition may result from treatment with systemic steroids and/or β_2 -agonists [187, 189]. Glucocorticoids promote gluconeogenesis in liver and antagonize insulin response in skeletal muscle and adipose tissue leading to hyperglycemia. However, treatment with inhaled steroids seems not to predispose for insulin resistance or diabetes [190].

8.6. Lung Mechanics. Obesity underlies many chronic conditions and its direct effects on lung mechanics may also contribute to development of asthma in these conditions. In obese subjects, the increased soft tissue compresses the thoracic cage leading to higher frequency of breathing, reduced peripheral airway diameter, and reduced lung volumes, which may lead to dyspnoea [37]. Recently it was shown that obesity is associated with increased resistance and dysfunction in peripheral airways [191]. However, something must exist to separate those obese subjects who develop asthma from those who do not. A weight loss study in obese nonallergic female asthmatics suggested that peripheral lung of the

obese patients developing asthma may be more collapsible when compared to obese controls [192]. Natural variation in the airway wall stiffness and thickness could provide explanation for the collapsibility and explain why some obese individuals are prone to develop hyperresponsiveness and asthma, and others are not. The airway wall properties could be determined by genetics or be a result of obesity-related altered metabolism [193].

8.7. Mitochondrial Dysfunction. Mitochondrial dysfunction has been suggested as a common pathogenetic mechanism of obesity, metabolic syndrome, and asthma [194]. Mitochondrial dysfunction and higher level of oxidative damage in mitochondria has also been described in patients with major depressive disorder (MDD) [195, 196]. In obese subjects, caloric excess overloads mitochondria, leading to overproduction of reactive oxygen species, damage to mitochondrial (and cellular) components, and mitochondrial loss. Mitochondrial dysfunction results in incomplete oxidation of fatty acids and increased circulating lipids. Some metabolically active lipids inhibit insulin signalling and may promote insulin resistance. The situation is aggravated by physical inactivity, since physical activity is a way of increasing mitochondrial activity [194, 197]. Similar changes in mitochondrial function occur in older age [198]. Mitochondrial dysfunction has also been shown in experimental allergic asthma in mice [199, 200] but evidence in human asthma is limited to genetic studies [194]. Asthma is, however, associated with oxidative stress [201], which may be partially derived from dysfunction of mitochondria but also accelerates mitochondrial dysfunction.

8.8. Disturbed Nitric Oxide Metabolism. Disturbed nitric oxide metabolism is also common for asthma and metabolic disorders. Obesity, metabolic syndrome, depression, cardiovascular diseases, and asthma have all been associated with increased level of asymmetric dimethyl arginine (ADMA) which is an inhibitor of all nitric oxide synthase (NOS) isoforms [202–206]. In obese patients with asthma, decreased ratio of L-arginine/ADMA in plasma and its association with worse outcome of asthma were shown [207]. Endothelial NOS is critical for vasodilatation, and its inhibition by ADMA may also lead to endothelial dysfunction, increased risk for atherosclerosis, and other cardiovascular diseases [208]. In airway diseases, the adverse effect of ADMA is thought to be mediated by enhancement of oxidative stress, which was shown in murine lung epithelial cells and in allergically inflamed lungs of mice after administration of ADMA [209, 210]. Increased ADMA may direct NOS to form superoxide instead of NO and lead to oxidative stress, mitochondrial damage, and dysfunction. Mitochondrial dysfunction in turn contributes to insulin resistance and type 2 diabetes by the route described above. The NOS enzyme(s) most critical for these effects remain to be determined. Another mechanism that may affect development of asthma in response to NOS inhibition is increased availability of L-arginine, the starting substance of NO to arginase-1/arginase-2 resulting in increased production of polyamines and proline. Polyamines function by increasing airway hyperresponsiveness and

eosinophil survival and proline is precursor of collagen, important for airway remodelling [211, 212]. Upregulated arginase-1 has also been demonstrated in patients with diabetes and in patients with heart failure [213, 214], postulating another common disease mechanism with asthma.

8.9. Leukotrienes. Leukotrienes construct another link between asthma and cardiovascular diseases. In asthma, cysteinyl leukotrienes (LTC₄, LTD₄, and LTE₄) are well-known mediators of bronchoconstriction, mucus production, and inflammatory cell recruitment in the airways and produced mainly by eosinophils and mast cells. Leukotrienes are derived from activation of 5-lipoxygenase (5-LO). 5-LO is upregulated also in atherosclerotic lesions and the increased number of 5-LO+ cells was described during progression of coronary heart disease [215]. Additionally, higher count of 5-LO+ cells was found in atherosclerotic plaque samples from symptomatic versus asymptomatic patients with internal carotid artery stenosis. Plaque samples from these symptomatic patients showed also higher levels of LTB₄ and active matrix metalloproteinases (MMP) 2 and 9 [216]. MMPs contribute to myocardial infarction by rupturing atherosclerotic plaques. Male hormones showed suppressive effects on 5-LO products [217] whereas estradiol stimulated release of cysteinyl leukotriene C₄ from mast cells *in vitro* [218]. These hormonal influences might partly explain the stronger association between cardiovascular diseases and asthma in women when compared to men.

9. Conclusions and Future Perspectives

Studies concentrating on evaluating the risk factors of asthma, impact on clinical disease, or impact on prognosis give clearly different benefits for the clinician. If a comorbid condition is a risk factor for asthma, it means that a person having the comorbid condition (e.g., being obese) but not having asthma has a higher probability of becoming asthmatic at some point later in his/her life. This data can help us guide, for example, the obese patient to lose weight and thereby reduce the future risk of becoming asthmatic. In addition, this knowledge can help us to target the preventive measures at population level to reduce the risk of developing a certain disease. However, to help the clinician to decide how to treat the patient we need to know what is the significance of the particular comorbidity for asthma control, severity, and lung function and how it affects therapy. To understand this we need clinical studies that evaluate the effect of the comorbidity on asthma disease activity and outcomes in asthma.

The mechanisms dealt in this review mainly originate from patient and experimental data measuring the different pathophysiological events, cells, and cell functions and possible mediators that might be relevant in the interaction between the particular comorbidity and asthma. Thus, these mechanisms rather represent the situation where the comorbid condition is affecting the clinical outcome of asthma. Instead, they may not prove that a certain mechanism or mediator is causative or mediating the development

TABLE 2: Comorbidities and their mechanistic links to asthma.

Comorbidities and their characteristic features/mechanisms	Mediators	Link of mechanism to asthma	Ref.
<i>Obesity, metabolic syndrome, diabetes</i>			
Adverse <i>in utero</i> conditions (such as maternal obesity)		Adverse conditions may induce, for example, epigenetic changes in foetus and lead to modified activity of genes important for immune system/metabolism.	[129–133]
Systemic inflammation and inflammasome activation	IL-6, CRP, TNF- α , IL-1 β	IL-6 and CRP associated with reduced lung function. IL-6 may promote Th17 differentiation and severe neutrophilic asthma. IL-1 β and IL-17 linked with development of AHR.	[138, 140, 143, 144, 154, 157]
Adipokine leptin elevated	Leptin	Airway reactivity correlated with visceral fat leptin expression. Adipokines may have direct effects on airways.	[158, 161–163]
Hyperglycemia/hyperinsulinemia	Glucose, insulin	Glucose and insulin may have direct effects on lungs promoting airway remodelling and AHR.	[179, 180, 182, 185]
Mechanical effects of obesity		Altered lung mechanics and dysfunction of peripheral airways in obese subjects: genetic properties of the airway wall may determine whether asthma develops.	[191–193]
Mitochondrial dysfunction/oxidative stress	Oxidants	Oxidative stress, for example, damages airway epithelia, modifies expression of inflammatory genes and has many deleterious effects in asthma.	[194, 199–201, 220]
Increased ADMA (inhibition of NOS)	ADMA	Decreased ratio of L-arg/ADMA was associated with worse outcome of asthma in obese patients. Effects of ADMA on asthma may be mediated by oxidants.	[202–204, 207, 209, 210]
<i>Coronary heart disease</i>			
Upregulated leukotrienes and 5-LO	LTs 5-LO	CysLTs are derived from 5-LO activity and well-known mediators of bronchoconstriction and mucus production.	[215–217]
Increased ADMA (inhibition of NOS)	ADMA	See the above effects of increased ADMA on asthma.	[207–210]
<i>Depression</i>			
Systemic inflammation and inflammasome activation	IL-6, CRP, TNF- α , IL-1 β	See the above effects of systemic inflammation on asthma. Inflammatory cytokines may also generate symptoms of depression. In mice studies IL-1 β upregulated serotonin transporter gene.	[149–151, 155, 156]
Increased ADMA (inhibition of NOS)	ADMA	See the above effects of increased ADMA on asthma.	[205–207, 209, 210]

AHR = airway hyperresponsiveness, ADMA = asymmetric dimethyl arginine, NOS = nitric oxide synthase, HPA = hypothalamic-pituitary-adrenal, 5-LO = 5-lipoxygenase, GR = glucocorticoid, L-arg = L-arginine, LT = leukotriene, cysLT = cysteinyl leukotriene, IL = interleukin, TNF = tumor necrosis factor, and CRP = C-reactive protein.

of asthma. That kind of study would require a different experimental setting. For example, measurement of certain mediators in large population samples and following whether these people later develop incident asthma or not might help to resolve those questions.

For comorbidities such as MBO or its components, DM2 and CVD, we lack studies that evaluate their effect on clinical asthma. There exists some preliminary evidence on the deleterious effects of obesity and mental disorders on asthma outcome (Figure 1). Clinical studies that evaluate long-term prognosis and the contribution of obesity (or other comorbidities) on asthma are needed. In addition, studies that evaluate changes in the comorbidity over time on asthma control, exacerbations, lung function, and drug usage are lacking. Obesity has been in focus during last years. However, obesity itself is associated with significant comorbidity (such as diabetes, cardiovascular diseases, and mental diseases) and lifestyle factors (such as smoking, unhealthy diet, chronic alcohol use, and low level of physical exercise) that may contribute to the asthma outcome. From the mechanistic point of view it may be rational to include patients with only single comorbidity (e.g., obesity) to asthma studies at the time (see, e.g., Table 1(a)). However, from the perspective of practicing respiratory specialist or general physician this is not optimal as most patients suffer from multimorbidity rather than from a single disease or a combination of two specific single diseases. For example, in Germany most patients (approximately 60%) have one or more diseases out of eight listed in addition to asthma [34]. In Scotland with a sample of almost 1.8 million people of all ages, multimorbidity affects one in four people [10]. Multimorbidity is often met in chronic diseases and in the elderly population [12]. Studies in patients with asthma that do not exclude patients because of comorbidities are thus warranted. Studies such as the Seinäjoki Adult Asthma Study (SAAS) that evaluate the long-term prognosis of new-onset asthma diagnosed at adult age and excludes only childhood-onset patients may shed light on this matter [219].

Many of the comorbidities associated with asthma occur as cluster of diseases rather than as a single combination of asthma with a specific comorbidity. As many of the suggested mediators are common to these diseases, we propose that there may not be a single mechanism for interaction between asthma and certain comorbidity and another separate mechanism for the interaction between asthma and second comorbidity, and so forth. Instead, we think that there exists a group of mechanisms that link with each other and most link with obesity and/or components of metabolic syndrome. Table 2 presents an overview of proposed mechanisms between asthma and certain comorbidities. Several mediators (e.g., IL-6 and ADMA) are associated with asthma and several comorbidities ranging from obesity to cardiovascular and psychiatric ones, suggesting that in addition to disease-specific mediators there may be mediators that drive the systemic inflammation playing a major role in the cluster of diseases around asthma.

These comorbidities may have common mechanisms and mediators. There exist some data that obesity and mental diseases may complicate asthma outcome, whereas data is

lacking on the effects of metabolic syndrome, diabetes, and cardiovascular diseases on the outcomes of clinical asthma.

Competing Interests

The authors declare that they have no competing interests.

References

- [1] T. To, S. Stanojevic, G. Moores et al., “Global asthma prevalence in adults: findings from the cross-sectional world health survey,” *BMC Public Health*, vol. 12, article 204, 2012.
- [2] S. B. de Nijs, L. N. Venekamp, and E. H. Bel, “Adult-onset asthma: is it really different?” *European Respiratory Review*, vol. 22, no. 127, pp. 44–52, 2013.
- [3] S. E. Wenzel, “Asthma phenotypes: the evolution from clinical to molecular approaches,” *Nature Medicine*, vol. 18, no. 5, pp. 716–725, 2012.
- [4] P. Ilmarinen, L. E. Tuomisto, and H. Kankaanranta, “Phenotypes, risk factors, and mechanisms of adult-onset asthma,” *Mediators of Inflammation*, vol. 2015, Article ID 514868, 19 pages, 2015.
- [5] H. Bisgaard and K. Bonnelykke, “Long-term studies of the natural history of asthma in childhood,” *Journal of Allergy and Clinical Immunology*, vol. 126, no. 2, pp. 187–197, 2010.
- [6] E. Rönmark, A. Lindberg, L. Watson, and B. Lundbäck, “Outcome and severity of adult onset asthma—report from the obstructive lung disease in northern Sweden studies (OLIN),” *Respiratory Medicine*, vol. 101, no. 11, pp. 2370–2377, 2007.
- [7] L. E. Tuomisto, P. Ilmarinen, and H. Kankaanranta, “Prognosis of new-onset asthma diagnosed at adult age,” *Respiratory Medicine*, vol. 109, no. 8, pp. 944–954, 2015.
- [8] A. Sood, C. Qualls, M. Schuyler et al., “Adult-onset asthma becomes the dominant phenotype among women by age 40 years: the longitudinal CARDIA study,” *Annals of the American Thoracic Society*, vol. 10, no. 3, pp. 188–197, 2013.
- [9] C. C. Imes and L. E. Burke, “The obesity epidemic: the United States as a cautionary tale for the rest of the world,” *Current Epidemiology Reports*, vol. 1, no. 2, pp. 82–88, 2014.
- [10] K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke, and B. Guthrie, “Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study,” *The Lancet*, vol. 380, no. 9836, pp. 37–43, 2012.
- [11] B. Pache, P. Vollenweider, G. Waeber, and P. Marques-Vidal, “Prevalence of measured and reported multimorbidity in a representative sample of the Swiss population,” *BMC Public Health*, vol. 15, article 164, 2015.
- [12] S. W. Mercer, “Comorbidity in asthma is important and requires a generalist approach,” *Primary Care Respiratory Journal*, vol. 23, no. 1, pp. 4–5, 2014.
- [13] J. M. Spergel, “From atopic dermatitis to asthma: the atopic march,” *Annals of Allergy, Asthma and Immunology*, vol. 105, no. 2, pp. 99–106, 2010.
- [14] J. Bousquet, J. M. Anto, P. Demoly et al., “Severe chronic allergic (and related) diseases: a uniform approach—a MeDALL—GA²LEN—ARIA position paper,” *International Archives of Allergy and Immunology*, vol. 158, no. 3, pp. 216–231, 2012.
- [15] C. A. Akdis, C. Bachert, C. Cingi et al., “Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and

- the American Academy of Allergy, Asthma & Immunology," *Journal of Allergy and Clinical Immunology*, vol. 131, no. 6, pp. 1479–1490, 2013.
- [16] L. F. Eichenfield, W. L. Tom, S. L. Chamlin et al., "Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis," *Journal of the American Academy of Dermatology*, vol. 70, no. 2, pp. 338–351, 2014.
- [17] D. P. Guh, W. Zhang, N. Bansback, Z. Amarsi, C. L. Birmingham, and A. H. Anis, "The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis," *BMC Public Health*, vol. 9, article 88, 2009.
- [18] L.-P. Boulet and M.-È. Boulay, "Asthma-related comorbidities," *Expert Review of Respiratory Medicine*, vol. 5, no. 3, pp. 377–393, 2011.
- [19] D. K. Ledford and R. F. Lockey, "Asthma and comorbidities," *Current Opinion in Allergy and Clinical Immunology*, vol. 13, no. 1, pp. 78–86, 2013.
- [20] M. Cazzola, A. Segreti, L. Calzetta, and P. Rogliani, "Comorbidities of asthma: current knowledge and future research needs," *Current Opinion in Pulmonary Medicine*, vol. 19, no. 1, pp. 36–41, 2013.
- [21] P. Kauppi, H. Kupiainen, A. Lindqvist et al., "Overlap syndrome of asthma and COPD predicts low quality of life," *Journal of Asthma*, vol. 48, no. 3, pp. 279–285, 2011.
- [22] Global Initiative for Asthma, *Global Strategy for Asthma Management and Prevention*, 2014, <http://www.ginasthma.org>.
- [23] Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2014, <http://www.goldcopd.org/>.
- [24] M. Miravittles, J. J. Soler-Cataluña, M. Calle et al., "Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable," *Archivos de Bronconeumología*, vol. 48, no. 7, pp. 247–257, 2012.
- [25] H. Kankaanranta, T. Harju, M. Kilpeläinen et al., "Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines," *Basic & Clinical Pharmacology and Toxicology*, vol. 116, no. 4, pp. 291–307, 2015.
- [26] M. Miravittles, J. J. Soler-Cataluña, M. Calle et al., "A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)," *Primary Care Respiratory Journal*, vol. 22, no. 1, pp. 117–121, 2013.
- [27] Ø. Karlstad, P. Nafstad, A. Tverdal, S. Skurtveit, and K. Furu, "Comorbidities in an asthma population 8–29 years old: a study from the Norwegian Prescription Database," *Pharmacoepidemiology and Drug Safety*, vol. 21, no. 10, pp. 1045–1052, 2012.
- [28] A. S. Gershon, C. Wang, J. Guan, and T. To, "Burden of comorbidity in individuals with asthma," *Thorax*, vol. 65, no. 7, pp. 612–618, 2010.
- [29] A. S. Gershon, J. Guan, C. Wang, J. C. Victor, and T. To, "Describing and quantifying asthma comorbidity: a population study," *PLoS ONE*, vol. 7, no. 5, Article ID e34967, 2012.
- [30] J. B. Soriano, G. T. Visick, H. Muellerova, N. Payvandi, and A. L. Hansell, "Patterns of comorbidities in newly diagnosed COPD and asthma in primary care," *Chest*, vol. 128, no. 4, pp. 2099–2107, 2005.
- [31] H. Kankaanranta, A. Lahdensuo, E. Moilanen, and P. J. Barnes, "Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review," *Respiratory Research*, vol. 5, article 17, 2004.
- [32] S. Suissa, A. Kezouh, and P. Ernst, "Inhaled corticosteroids and risks of diabetes onset and progression," *American Journal of Medicine*, vol. 123, no. 11, pp. 1001–1006, 2010.
- [33] K. Mattishent, M. Thavarajah, P. Blanco, D. Gilbert, A. M. Wilson, and Y. K. Loke, "Meta-review: adverse effects of inhaled corticosteroids relevant to older patients," *Drugs*, vol. 74, no. 5, pp. 539–547, 2014.
- [34] H. Steppuhn, U. Langen, T. Keil, and C. Scheidt-Nave, "Chronic disease co-morbidity of asthma and unscheduled asthma care among adults: results of the national telephone health interview survey German health update (GEDA) 2009 and 2010," *Primary Care Respiratory Journal*, vol. 23, no. 1, pp. 22–29, 2014.
- [35] R. Hakola, P. Kauppi, T. Leino et al., "Persistent asthma, comorbid conditions and the risk of work disability: a prospective cohort study," *Allergy*, vol. 66, no. 12, pp. 1598–1603, 2011.
- [36] D. Gibeon, K. Batuwita, M. Osmond et al., "Obesity-associated severe asthma represents a distinct clinical phenotype. Analysis of the british thoracic society difficult asthma registry patient cohort according to BMI," *Chest*, vol. 143, no. 2, pp. 406–414, 2013.
- [37] Z. Ali and C. S. Ulrik, "Obesity and asthma: a coincidence or a causal relationship? A systematic review," *Respiratory Medicine*, vol. 107, no. 9, pp. 1287–1300, 2013.
- [38] P. Sivapalan, Z. Diamant, and C. S. Ulrik, "Obesity and asthma: current knowledge and future needs," *Current Opinion in Pulmonary Medicine*, vol. 21, no. 1, pp. 80–85, 2014.
- [39] L. Wang, K. Wang, X. Gao, T. K. Paul, J. Cai, and Y. Wang, "Sex difference in the association between obesity and asthma in U.S. adults: findings from a national study," *Respiratory Medicine*, vol. 109, no. 8, pp. 955–962, 2015.
- [40] B. Brumpton, A. Langhammer, P. Romundstad, Y. Chen, and X.-M. Mai, "General and abdominal obesity and incident asthma in adults: the HUNT study," *European Respiratory Journal*, vol. 41, no. 2, pp. 323–329, 2013.
- [41] N. Assad, C. Qualls, L. J. Smith et al., "Body mass index is a stronger predictor than the metabolic syndrome for future asthma in women. The longitudinal CARDIA study," *American Journal of Respiratory and Critical Care Medicine*, vol. 188, no. 3, pp. 319–326, 2013.
- [42] M. Ruotsalainen, V. Sidoroff, E. Piippo-Savolainen, M. K. Hyvärinen, and M. Korppi, "Association between overweight and asthma or allergy: results from a prospective 27-year post-bronchiolitis follow-up," *Current Pediatric Research*, vol. 16, no. 2, pp. 95–100, 2012.
- [43] J. I. Peters, J. M. McKinney, B. Smith, P. Wood, E. Forkner, and A. D. Galbreath, "Impact of obesity in asthma: evidence from a large prospective disease management study," *Annals of Allergy, Asthma and Immunology*, vol. 106, no. 1, pp. 30–35, 2011.
- [44] S. Pakhale, S. Doucette, K. Vandemheen et al., "A comparison of obese and nonobese people with asthma: exploring an asthma-obesity interaction," *Chest*, vol. 137, no. 6, pp. 1316–1323, 2010.
- [45] S. Scott, J. Currie, P. Albert, P. Calverley, and J. P. H. Wilding, "Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma," *Chest*, vol. 141, no. 3, pp. 616–624, 2012.
- [46] A. Lessard, H. Turcotte, Y. Cormier, and L.-P. Boulet, "Obesity and asthma: a specific phenotype?" *Chest*, vol. 134, no. 2, pp. 317–323, 2008.
- [47] F. Holguin, E. R. Bleecker, W. W. Busse et al., "Obesity and asthma: an association modified by age of asthma onset," *Journal of Allergy and Clinical Immunology*, vol. 127, no. 6, pp. 1486.e2–1493.e2, 2011.

- [48] D. Gibeon, K. Batuwita, M. Osmond et al., "Obesity-associated severe asthma represents a distinct clinical phenotype analysis of the british thoracic society diffi cult asthma registry patient cohort according to BMI," *Chest*, vol. 143, no. 2, pp. 406–414, 2013.
- [49] A. Bruno, E. Pace, F. Cibella, and P. Chanez, "Body mass index and comorbidities in adult severe asthmatics," *BioMed Research International*, vol. 2014, Article ID 607192, 7 pages, 2014.
- [50] A. K. Ramasamy, N. Gupta, and R. Kumar, "Impact of obesity on bronchial asthma in Indian population," *Lung India*, vol. 31, no. 2, pp. 121–126, 2014.
- [51] G. Ciprandi, I. Schiavetti, R. B. Fontana, V. Sorbello, and F. L. M. Ricciardolo, "Overweight and obesity as risk factors for impaired lung function in patients with asthma: a real-life experience," *Allergy and Asthma Proceedings*, vol. 35, no. 4, pp. e62–e71, 2014.
- [52] B. Taylor, D. Mannino, C. Brown, D. Crocker, N. Twum-Baah, and F. Holguin, "Body mass index and asthma severity in the National Asthma Survey," *Thorax*, vol. 63, no. 1, pp. 14–20, 2008.
- [53] J. E. Cotes, D. J. Chinn, and J. W. Reed, "Body mass, fat percentage, and fat free mass as reference variables for lung function: effects on terms for age and sex," *Thorax*, vol. 56, no. 11, pp. 839–844, 2001.
- [54] M. S. Biring, M. I. Lewis, J. T. Liu, and Z. Mohsenifar, "Pulmonary physiologic changes of morbid obesity," *The American Journal of the Medical Sciences*, vol. 318, no. 5, pp. 293–297, 1999.
- [55] G. N. Bedell, W. R. Wilson, and P. M. Seebohm, "Pulmonary function in obese persons," *Journal of Clinical Investigation*, vol. 37, no. 7, pp. 1049–1060, 1958.
- [56] M. Schatz, R. S. Zeiger, S. J. Yang et al., "Prospective study on the relationship of obesity to asthma impairment and risk," *The Journal of Allergy and Clinical Immunology: In Practice*, vol. 3, no. 4, pp. 560.e1–565.e1, 2015.
- [57] B. Stenius-Aarniala, T. Poussa, J. Kvarnström, E.-L. Grönlund, M. Ylikahri, and P. Mustajoki, "Immediate and long term effects of weight reduction in obese people with asthma: randomised controlled study," *British Medical Journal*, vol. 320, no. 7238, pp. 827–832, 2000.
- [58] H. A. Scott, P. G. Gibson, M. L. Garg et al., "Dietary restriction and exercise improve airway inflammation and clinical outcomes in overweight and obese asthma: a randomized trial," *Clinical and Experimental Allergy*, vol. 43, no. 1, pp. 36–49, 2013.
- [59] S. Pakhale, J. Baron, R. Dent, K. Vandemheen, and S. D. Aaron, "Effects of weight loss on airway responsiveness in obese adults with asthma. Does weight loss lead to reversibility of asthma?" *Chest*, vol. 147, no. 6, pp. 1582–1590, 2015.
- [60] L.-P. Boulet, H. Turcotte, J. Martin, and P. Poirier, "Effect of bariatric surgery on airway response and lung function in obese subjects with asthma," *Respiratory Medicine*, vol. 106, no. 5, pp. 651–660, 2012.
- [61] A. van Huisstede, A. Rudolphus, M. Castro Cabezas et al., "Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma," *Thorax*, vol. 70, no. 7, pp. 659–667, 2015.
- [62] A. E. Dixon, R. E. Pratley, P. M. Forgione et al., "Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control and inflammation," *Journal of Allergy and Clinical Immunology*, vol. 128, no. 3, pp. 508–515, 2011.
- [63] K. Hasegawa, Y. Tsugawa, Y. Chang, and C. A. Camargo, "Risk of an asthma exacerbation after bariatric surgery in adults," *Journal of Allergy and Clinical Immunology*, vol. 136, no. 2, pp. 288–294, 2015.
- [64] J. V. Garmendia, D. Moreno, A. H. García, and J. B. De Sanctis, "Metabolic syndrome and asthma," *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery*, vol. 8, no. 1, pp. 60–66, 2014.
- [65] B. M. Brumpton, C. A. Camargo Jr., P. R. Romundstad, A. Langhammer, Y. Chen, and X.-M. Mai, "Metabolic syndrome and incidence of asthma in adults: the HUNT study," *European Respiratory Journal*, vol. 42, no. 6, pp. 1495–1502, 2013.
- [66] E. J. Lee, K. H. In, E. S. Ha et al., "Asthma-like symptoms are increased in the metabolic syndrome," *Journal of Asthma*, vol. 46, no. 4, pp. 339–342, 2009.
- [67] M. B. Fessler, "Next stop for HDL: the lung," *Clinical and Experimental Allergy*, vol. 42, no. 3, pp. 340–342, 2013.
- [68] M. B. Fessler, "Revisiting 'Good' and 'Bad' cholesterol. The battle over flow through arteries now shifts to flow through airways," *American Journal of Respiratory and Critical Care Medicine*, vol. 191, no. 9, pp. 969–970, 2015.
- [69] P. L. Enright, B. J. Ward, R. P. Tracy, and E. C. Lasser, "Asthma and its association with cardiovascular disease in the elderly. The cardiovascular health study research group," *Journal of Asthma*, vol. 33, no. 1, pp. 45–53, 1996.
- [70] C. Picado, R. Deulofeu, R. Leonart et al., "Lipid and protein metabolism in asthma. Effects of diet and corticosteroid therapy," *Allergy*, vol. 54, no. 6, pp. 569–575, 1999.
- [71] A. V. Barochia, M. Kaler, R. A. Cuento et al., "Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV₁ in atopic asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 191, no. 9, pp. 990–1000, 2015.
- [72] S. Dogra, C. I. Arden, and J. Baker, "The relationship between age of asthma onset and cardiovascular disease in Canadians," *Journal of Asthma*, vol. 44, no. 10, pp. 849–854, 2007.
- [73] T. Zhang, B. C. Carleton, R. J. Prosser, and A. M. Smith, "The added burden of comorbidity in patients with asthma," *Journal of Asthma*, vol. 46, no. 10, pp. 1021–1026, 2009.
- [74] D. A. Hickson, R. L. Wilhite, M. F. Petrini, W. B. White, and C. Burchfiel, "Asthma and asthma severity among african american adults in the Jackson Heart Study," *Journal of Asthma*, vol. 46, no. 4, pp. 421–428, 2009.
- [75] M. Johnson, J. Nriagu, A. Hammad, K. Savoie, and H. Jamil, "Asthma, environmental risk factors, and hypertension among Arab Americans in metro Detroit," *Journal of Immigrant and Minority Health*, vol. 12, no. 5, pp. 640–651, 2010.
- [76] S. C. Christiansen, M. Schatz, S.-J. Yang, E. Ngor, W. Chen, and B. L. Zuraw, "Hypertension and asthma: a comorbid relationship," *Journal of Allergy and Clinical Immunology in Practice*, vol. 2, pp. S2213–2198, 2015, [Epub ahead of print].
- [77] N. Nurminen, S. Oikarinen, and H. Hyöty, "Virus infections as potential targets of preventive treatments for type 1 diabetes," *The Review of Diabetic Studies*, vol. 9, no. 4, pp. 260–271, 2012.
- [78] S. F. Ehrlich, C. P. Quesenberry Jr., S. K. Van Den Eeden, J. Shan, and A. Ferrara, "Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer," *Diabetes Care*, vol. 33, no. 1, pp. 55–60, 2010.
- [79] S. F. Thomsen, D. L. Duffy, K. O. Kyvik, A. Skytthe, and V. Backer, "Risk of asthma in adult twins with type 2 diabetes and increased body mass index," *Allergy*, vol. 66, no. 4, pp. 562–568, 2011.
- [80] M. Hashemzadeh and M. R. Movahed, "The occurrence of asthma in hospitalized patients with type 2 diabetes mellitus," *Internal Medicine Journal*, vol. 39, no. 10, pp. 699–701, 2009.


- [81] N. T. Mueller, W.-P. Koh, A. O. Odegaard, M. D. Gross, J.-M. Yuan, and M. A. Pereira, "Asthma and the risk of type 2 diabetes in the Singapore Chinese Health Study," *Diabetes Research and Clinical Practice*, vol. 99, no. 2, pp. 192–199, 2013.
- [82] P. M. O'Byrne, S. Rennard, H. Gerstein et al., "Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids," *Respiratory Medicine*, vol. 106, no. 11, pp. 1487–1493, 2012.
- [83] J. S. Rana, M. A. Mittleman, J. Sheikh et al., "Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women," *Diabetes Care*, vol. 27, no. 10, pp. 2478–2484, 2004.
- [84] Y. Song, A. Klevak, J. E. Manson, J. E. Buring, and S. Liu, "Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study," *Diabetes Research and Clinical Practice*, vol. 90, no. 3, pp. 365–371, 2010.
- [85] H. D. Yun, E. Knoebel, Y. Fenta et al., "Asthma and proinflammatory conditions: a population-based retrospective matched cohort study," *Mayo Clinic Proceedings*, vol. 87, no. 10, pp. 953–960, 2012.
- [86] K. Torén and N. B. Lindholm, "Do patients with severe asthma run an increased risk from ischaemic heart disease?" *International Journal of Epidemiology*, vol. 25, no. 3, pp. 617–620, 1996.
- [87] V. Bellia, C. Pedone, F. Catalano et al., "Asthma in the elderly: mortality rate and associated risk factors for mortality," *Chest*, vol. 132, no. 4, pp. 1175–1182, 2007.
- [88] H. M. Lee, S. T. Truong, and N. D. Wong, "Association of adult-onset asthma with specific cardiovascular conditions," *Respiratory Medicine*, vol. 106, no. 7, pp. 948–953, 2012.
- [89] C. Iribarren, I. V. Tolstykh, and M. D. Eisner, "Are patients with asthma at increased risk of coronary heart disease?" *International Journal of Epidemiology*, vol. 33, no. 4, pp. 743–748, 2004.
- [90] M. Szklo, R. Barnes, A. Folsom et al., "The atherosclerosis risk in communities (ARIC) study: design and objectives," *American Journal of Epidemiology*, vol. 129, no. 4, pp. 687–702, 1989.
- [91] J. G. Schanen, C. Iribarren, E. Shahar et al., "Asthma and incident cardiovascular disease: the Atherosclerosis Risk in Communities study," *Thorax*, vol. 60, no. 8, pp. 633–638, 2005.
- [92] S. Onufrak, J. Abramson, and V. Vaccarino, "Adult-onset asthma is associated with increased carotid atherosclerosis among women in the atherosclerosis risk in communities (ARIC) study," *Atherosclerosis*, vol. 195, no. 1, pp. 129–137, 2007.
- [93] S. J. Onufrak, J. L. Abramson, H. D. Austin, F. Holguin, W. M. McClellan, and L. V. Vaccarino, "Relation of adult-onset asthma to coronary heart disease and stroke," *American Journal of Cardiology*, vol. 101, no. 9, pp. 1247–1252, 2008.
- [94] C. Iribarren, I. V. Tolstykh, M. K. Miller, E. Sobel, and M. D. Eisner, "Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts," *American Journal of Epidemiology*, vol. 176, no. 11, pp. 1014–1024, 2012.
- [95] M. C. Tattersall, M. Guo, C. E. Korcarz et al., "Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 35, no. 6, pp. 1520–1525, 2015.
- [96] Y. Çolak, S. Afzal, B. G. Nordestgaard, and P. Lange, "Characteristics and prognosis of never-smokers and smokers with asthma in the Copenhagen general population study. A prospective cohort study," *American Journal of Respiratory and Critical Care Medicine*, vol. 192, no. 2, pp. 172–181, 2015.
- [97] M. Pujades-Rodriguez, J. George, A. D. Shah et al., "Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937 360 people in England: lifetime risks and implications for risk prediction," *International Journal of Epidemiology*, vol. 44, no. 1, pp. 129–141, 2015.
- [98] J. Garcia-Aymerich, "The role of smoking in the association between asthma and cardiovascular disease. An example of poorly controlled confounding," *American Journal of Respiratory and Critical Care Medicine*, vol. 192, no. 2, p. 123, 2015.
- [99] M. Opolski and I. Wilson, "Asthma and depression: a pragmatic review of the literature and recommendations for future research," *Clinical Practice and Epidemiology in Mental Health*, vol. 1, article 18, 2005.
- [100] T. Ritz, A. E. Meuret, A. F. Trueba, A. Fritzsche, and A. von Leupoldt, "Psychosocial factors and behavioral medicine interventions in asthma," *Journal of Consulting and Clinical Psychology*, vol. 81, no. 2, pp. 231–250, 2013.
- [101] K. M. Scott, M. Von Korff, J. Ormel et al., "Mental disorders among adults with asthma: results from the world mental health Survey," *General Hospital Psychiatry*, vol. 29, no. 2, pp. 123–133, 2007.
- [102] E. B. Weiser, "The prevalence of anxiety disorders among adults with asthma: a meta-analytic review," *Journal of Clinical Psychology in Medical Settings*, vol. 14, no. 4, pp. 297–307, 2007.
- [103] M. Jiang, P. Qin, and X. Yang, "Comorbidity between depression and asthma via immune-inflammatory pathways: a meta-analysis," *Journal of Affective Disorders*, vol. 166, pp. 22–29, 2014.
- [104] J. De Miguel Diez, V. Hernandez-Barrera, L. P. Maestu, P. C. Garrido, T. Gomez Garcia, and R. Jimenez Garcia, "Psychiatric comorbidity in asthma patients. Associated factors," *Journal of Asthma*, vol. 48, no. 3, pp. 253–258, 2011.
- [105] R. D. Goodwin, F. Jacobi, and W. Thefeld, "Mental disorders and asthma in the community," *Archives of General Psychiatry*, vol. 60, no. 11, pp. 1125–1130, 2003.
- [106] C. Q. Jiang, A. Loerbroks, K.-B. H. Lam et al., "Mental health and asthma in China: the Guangzhou Biobank Cohort Study," *International Journal of Behavioral Medicine*, vol. 20, no. 2, pp. 259–264, 2013.
- [107] K. O. Wong, B. H. Rowe, J. Douwes, and A. Senthilselvan, "Asthma and wheezing are associated with depression and anxiety in adults: an analysis from 54 countries," *Pulmonary Medicine*, vol. 2013, Article ID 929028, 10 pages, 2013.
- [108] W. J. Katon, L. Richardson, P. Lozano, and E. McCauley, "The relationship of asthma and anxiety disorders," *Psychosomatic Medicine*, vol. 66, no. 3, pp. 349–355, 2004.
- [109] M. J. Slattery and M. J. Essex, "Specificity in the association of anxiety, depression, and atopic disorders in a community sample of adolescents," *Journal of Psychiatric Research*, vol. 45, no. 6, pp. 788–795, 2011.
- [110] I. Olsson and A. A. Dahl, "Personality problems are considerably associated with somatic morbidity and health care utilisation," *European Psychiatry*, vol. 24, no. 7, pp. 442–449, 2009.
- [111] N. Iessa, M. L. Murray, S. Curran, and I. C. K. Wong, "Asthma and suicide-related adverse events: a review of observational studies," *European Respiratory Review*, vol. 20, no. 122, pp. 287–292, 2011.
- [112] M. S. Pedersen, M. E. Benros, E. Agerbo, A. D. Børglum, and P. B. Mortensen, "Schizophrenia in patients with atopic disorders

- with particular emphasis on asthma: a Danish population-based study,” *Schizophrenia Research*, vol. 138, no. 1, pp. 58–62, 2012.
- [113] K. M. Scott, M. V. Korff, J. Alonso et al., “Childhood adversity, early-onset depressive/anxiety disorders, and adult-onset asthma,” *Psychosomatic Medicine*, vol. 70, no. 9, pp. 1035–1043, 2008.
- [114] J. Alonso, P. de Jonge, C. C. W. Lim et al., “Association between mental disorders and subsequent adult onset asthma,” *Journal of Psychiatric Research*, vol. 59, pp. 179–188, 2014.
- [115] N. Hutter, A. Knecht, and H. Baumeister, “Health care costs in persons with asthma and comorbid mental disorders. A systematic review,” *General Hospital Psychiatry*, vol. 33, no. 5, pp. 443–453, 2011.
- [116] K. L. Lavoie, S. L. Bacon, S. Barone, A. Cartier, B. Ditto, and M. Labrecque, “What is worse for asthma control and quality of life: depressive disorders, anxiety disorders, or both?” *Chest*, vol. 130, no. 4, pp. 1039–1047, 2006.
- [117] K. L. Lavoie, M. Boudreau, A. Plourde, T. S. Campbell, and S. L. Bacon, “Association between generalized anxiety disorder and asthma morbidity,” *Psychosomatic Medicine*, vol. 73, no. 6, pp. 504–513, 2011.
- [118] H. Favreau, S. L. Bacon, M. Labrecque, and K. L. Lavoie, “Prospective impact of panic disorder and panic-anxiety on asthma control, health service use, and quality of life in adult patients with asthma over a 4-year follow-up,” *Psychosomatic Medicine*, vol. 76, no. 2, pp. 147–155, 2014.
- [119] A. ten Brinke, M. E. Ouwkerk, A. H. Zwinderman, P. Spinhoven, and E. H. Bel, “Psychopathology in patients with severe asthma is associated with increased health care utilization,” *American Journal of Respiratory and Critical Care Medicine*, vol. 163, no. 5, pp. 1093–1096, 2001.
- [120] K. Ouellet, S. L. Bacon, M. Boudreau, A. Plourde, G. Moullec, and K. L. Lavoie, “Individual and combined impact of cigarette smoking, anxiety, and mood disorders on asthma control,” *Nicotine & Tobacco Research*, vol. 14, no. 8, pp. 961–969, 2012.
- [121] M. Boudreau, S. L. Bacon, K. Ouellet, A. Jacob, and K. L. Lavoie, “Mediator effect of depressive symptoms on the association between BMI and asthma control in adults,” *Chest*, vol. 146, no. 2, pp. 348–354, 2014.
- [122] S. G. Kapadia, C. Wei, S. J. Bartlett, J. Lang, R. A. Wise, and A. E. Dixon, “Obesity and symptoms of depression contribute independently to the poor asthma control of obesity,” *Respiratory Medicine*, vol. 108, no. 8, pp. 1100–1107, 2014.
- [123] M. B. Stein, B. J. Cox, T. O. Afifi, S.-L. Belik, and J. Sareen, “Does co-morbid depressive illness magnify the impact of chronic physical illness? A population-based perspective,” *Psychological Medicine*, vol. 36, no. 5, pp. 587–596, 2006.
- [124] A. van Huisstede, A. Rudolphus, A. van Schadewijk et al., “Bronchial and systemic inflammation in morbidly obese subjects with asthma: a biopsy study,” *American Journal of Respiratory and Critical Care Medicine*, vol. 190, no. 8, pp. 951–954, 2014.
- [125] D. Desai, C. Newby, F. A. Symon et al., “Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma,” *American Journal of Respiratory and Critical Care Medicine*, vol. 188, no. 6, pp. 657–663, 2013.
- [126] I. H. van Veen, A. Ten Brinke, P. J. Sterk, K. F. Rabe, and E. H. Bel, “Airway inflammation in obese and nonobese patients with difficult-to-treat asthma,” *Allergy*, vol. 63, no. 5, pp. 570–574, 2008.
- [127] T. J. T. Sutherland, J. O. Cowan, S. Young et al., “The association between obesity and asthma: interactions between systemic and airway inflammation,” *American Journal of Respiratory and Critical Care Medicine*, vol. 178, no. 5, pp. 469–475, 2008.
- [128] W. C. Moore, A. T. Hastie, X. Li et al., “Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis,” *The Journal of Allergy and Clinical Immunology*, vol. 133, no. 6, pp. 1557–1563.e5, 2014.
- [129] J. R. O’Reilly and R. M. Reynolds, “The risk of maternal obesity to the long-term health of the offspring,” *Clinical Endocrinology*, vol. 78, no. 1, pp. 9–16, 2013.
- [130] E. Forno, O. M. Young, R. Kumar, H. Simhan, and J. C. Celedón, “Maternal obesity in pregnancy, gestational weight gain, and risk of childhood asthma,” *Pediatrics*, vol. 134, no. 2, pp. e535–e546, 2014.
- [131] R. C. Johnson and R. F. Schoeni, “Early-life origins of adult disease: national longitudinal population-based study of the United States,” *American Journal of Public Health*, vol. 101, no. 12, pp. 2317–2324, 2011.
- [132] C. J. Smith and K. K. Ryckman, “Epigenetic and developmental influences on the risk of obesity, diabetes, and metabolic syndrome,” *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, vol. 8, pp. 295–302, 2015.
- [133] P. D. Gluckman, M. A. Hanson, C. Cooper, and K. L. Thornburg, “Effect of in utero and early-life conditions on adult health and disease,” *The New England Journal of Medicine*, vol. 359, no. 1, pp. 61–73, 2008.
- [134] A. Danese, T. E. Moffitt, C. M. Pariante, A. Ambler, R. Poulton, and A. Caspi, “Elevated inflammation levels in depressed adults with a history of childhood maltreatment,” *Archives of General Psychiatry*, vol. 65, no. 4, pp. 409–416, 2008.
- [135] G. E. Miller and S. W. Cole, “Clustering of depression and inflammation in adolescents previously exposed to childhood adversity,” *Biological Psychiatry*, vol. 72, no. 1, pp. 34–40, 2012.
- [136] P. F. Coogan, L. A. Wise, G. T. O’Connor, T. A. Brown, J. R. Palmer, and L. Rosenberg, “Abuse during childhood and adolescence and risk of adult-onset asthma in African American women,” *The Journal of Allergy and Clinical Immunology*, vol. 131, no. 4, pp. 1058–1063, 2013.
- [137] R. J. Van Lieshout, J. Bienenstock, and G. M. MacQueen, “A review of candidate pathways underlying the association between asthma and major depressive disorder,” *Psychosomatic Medicine*, vol. 71, no. 2, pp. 187–195, 2009.
- [138] L. G. Wood, K. J. Baines, J. Fu, H. A. Scott, and P. G. Gibson, “The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma,” *Chest*, vol. 142, no. 1, pp. 86–93, 2012.
- [139] K. J. Baines, V. Backer, P. G. Gibson, H. Powel, and C. M. Porsbjerg, “Impaired lung function is associated with systemic inflammation and macrophage activation,” *The European Respiratory Journal*, vol. 45, no. 2, pp. 557–559, 2015.
- [140] J. B. Morjaria, K. S. Babu, P. Vijayanand, A. J. Chauhan, D. E. Davies, and S. T. Holgate, “Sputum IL-6 concentrations in severe asthma and its relationship with FEV₁,” *Thorax*, vol. 66, no. 6, p. 537, 2011.
- [141] H. Kankaanranta, P. Ilmarinen, X. Zhang et al., “Tumour necrosis factor- α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF- κ B and AP-1,” *PLoS ONE*, vol. 9, no. 2, Article ID e90298, 2014.
- [142] C. A. Hunter and S. A. Jones, “IL-6 as a keystone cytokine in health and disease,” *Nature Immunology*, vol. 16, no. 5, pp. 448–457, 2015.

- [143] M. Rincon and C. G. Irvin, "Role of IL-6 in asthma and other inflammatory pulmonary diseases," *International Journal of Biological Sciences*, vol. 8, no. 9, pp. 1281–1290, 2012.
- [144] C. Irvin, I. Zafar, J. Good et al., "Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma," *The Journal of Allergy and Clinical Immunology*, vol. 134, no. 5, pp. 1175.e7–1186.e7, 2014.
- [145] M. Jagannathan-Bogdan, M. E. McDonnell, H. Shin et al., "Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes," *Journal of Immunology*, vol. 186, no. 2, pp. 1162–1172, 2011.
- [146] E. Fabbrini, M. Cella, S. A. McCartney et al., "Association between specific adipose tissue CD4⁺ T-cell populations and insulin resistance in obese individuals," *Gastroenterology*, vol. 145, no. 2, pp. 366.e1–374.e3, 2013.
- [147] V. Schmitt, L. Rink, and P. Uciechowski, "The Th17/Treg balance is disturbed during aging," *Experimental Gerontology*, vol. 48, no. 12, pp. 1379–1386, 2013.
- [148] C. Brandenberger, N. Li, D. N. Jackson-Humbles, C. E. Rockwell, J. G. Wagner, and J. R. Harkema, "Enhanced allergic airway disease in old mice is associated with a Th17 response," *Clinical & Experimental Allergy*, vol. 44, no. 10, pp. 1282–1292, 2014.
- [149] T. Wang, Y. Ji, Y. Yang et al., "Transcriptomic profiling of peripheral blood CD4⁺ T-cells in asthmatics with and without depression," *Gene*, vol. 565, no. 2, pp. 282–287, 2015.
- [150] O. J. G. Schiepers, M. C. Wichers, and M. Maes, "Cytokines and major depression," *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, vol. 29, no. 2, pp. 201–217, 2005.
- [151] M. C. Wichers and M. Maes, "The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression," *Journal of Psychiatry & Neuroscience*, vol. 29, no. 1, pp. 11–17, 2004.
- [152] M. Haneklaus and L. A. O'Neill, "NLRP3 at the interface of metabolism and inflammation," *Immunological Reviews*, vol. 265, no. 1, pp. 53–62, 2015.
- [153] M. Iwata, K. T. Ota, and R. S. Duman, "The inflammasome: pathways linking psychological stress, depression, and systemic illnesses," *Brain, Behavior, and Immunity*, vol. 31, pp. 105–114, 2013.
- [154] S. R. Kim, D. I. Kim, S. H. Kim et al., "NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation," *Cell Death & Disease*, vol. 5, no. 10, Article ID e1498, 2014.
- [155] C.-B. Zhu, K. M. Lindler, A. W. Owens, L. C. Daws, R. D. Blakely, and W. A. Hewlett, "Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters," *Neuropsychopharmacology*, vol. 35, no. 13, pp. 2510–2520, 2010.
- [156] S. Ramamoorthy, J. D. Ramamoorthy, P. D. Prasad et al., "Regulation of the human serotonin transporter by interleukin-1 β ," *Biochemical and Biophysical Research Communications*, vol. 216, no. 2, pp. 560–567, 1995.
- [157] H. Y. Kim, H. J. Lee, Y.-J. Chang et al., "Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity," *Nature Medicine*, vol. 20, no. 1, pp. 54–61, 2014.
- [158] T. J. T. Sutherland, M. R. Sears, C. R. McLachlan, R. Poulton, and R. J. Hancox, "Leptin, adiponectin, and asthma: findings from a population-based cohort study," *Annals of Allergy, Asthma & Immunology*, vol. 103, no. 2, pp. 101–107, 2009.
- [159] M. Canöz, F. Erdenen, H. Uzun, C. Müderrisoğlu, and S. Aydin, "The relationship of inflammatory cytokines with asthma and obesity," *Clinical and Investigative Medicine*, vol. 31, no. 6, pp. E373–E379, 2008.
- [160] C. E. Ruhl and J. E. Everhart, "Leptin concentrations in the United States: relations with demographic and anthropometric measures," *The American Journal of Clinical Nutrition*, vol. 74, no. 3, pp. 295–301, 2001.
- [161] O. Sideleva, B. T. Suratt, K. E. Black et al., "Obesity and asthma: an inflammatory disease of adipose tissue not the airway," *American Journal of Respiratory and Critical Care Medicine*, vol. 186, no. 7, pp. 598–605, 2012.
- [162] S. A. Shore, I. N. Schwartzman, M. S. Mellema, L. Flynt, A. Imrich, and R. A. Johnston, "Effect of leptin on allergic airway responses in mice," *The Journal of Allergy and Clinical Immunology*, vol. 115, no. 1, pp. 103–109, 2005.
- [163] J. H. J. Vernooy, N. D. J. Ubags, G. G. Brusselle et al., "Leptin as regulator of pulmonary immune responses: involvement in respiratory diseases," *Pulmonary Pharmacology & Therapeutics*, vol. 26, no. 4, pp. 464–472, 2013.
- [164] S. Leivo-Korpela, L. Lehtimäki, K. Vuolteenaho et al., "Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma," *Journal of Inflammation*, vol. 8, article 12, 2011.
- [165] A. Bruno, E. Pace, P. Chanaz et al., "Leptin and leptin receptor expression in asthma," *The Journal of Allergy and Clinical Immunology*, vol. 124, no. 2, pp. 237.e1–237.e4, 2009.
- [166] J. H. Shin, J. H. Kim, W. Y. Lee, and J. Y. Shim, "The expression of adiponectin receptors and the effects of adiponectin and leptin on airway smooth muscle cells," *Yonsei Medical Journal*, vol. 49, no. 5, pp. 804–810, 2008.
- [167] P. Ilmarinen and H. Kankaanranta, "Eosinophil apoptosis as a therapeutic target in allergic asthma," *Basic & Clinical Pharmacology & Toxicology*, vol. 114, no. 1, pp. 109–117, 2014.
- [168] S. Conus, A. Bruno, and H.-U. Simon, "Leptin is an eosinophil survival factor," *The Journal of Allergy and Clinical Immunology*, vol. 116, no. 6, pp. 1228–1234, 2005.
- [169] H. Lai, N. Lin, Z. Xing, H. Weng, and H. Zhang, "Association between the level of circulating adiponectin and prediabetes: a meta-analysis," *Journal of Diabetes Investigation*, vol. 6, no. 4, pp. 416–429, 2015.
- [170] A. Sood, C. Qualls, M. Schuyler et al., "Low serum adiponectin predicts future risk for asthma in women," *American Journal of Respiratory and Critical Care Medicine*, vol. 186, no. 1, pp. 41–47, 2012.
- [171] A. Sood and S. A. Shore, "Adiponectin, leptin, and resistin in asthma: basic mechanisms through population studies," *Journal of Allergy*, vol. 2013, Article ID 785835, 15 pages, 2013.
- [172] S. K. Davis, S. Y. Gebreab, R. Xu et al., "Association of adiponectin with type 2 diabetes and hypertension in African American men and women: the Jackson Heart study," *BMC Cardiovascular Disorders*, vol. 15, article 13, 2015.
- [173] A. Sood, E. Dominic, and C. Qualls, "Serum adiponectin is associated with adverse outcomes of asthma in men but not in women," *Frontiers in Pharmacology*, vol. 2, article 55, 2011.
- [174] K. M. Ajuwon and M. E. Spurlock, "Adiponectin inhibits LPS-induced NF- κ B activation and IL-6 production and increases PPAR γ 2 expression in adipocytes," *The American Journal of Physiology—Regulatory Integrative and Comparative Physiology*, vol. 288, no. 5, pp. R1220–R1225, 2005.
- [175] E. J. Folco, V. Z. Rocha, M. López-Illasaca, and P. Libby, "Adiponectin inhibits pro-inflammatory signaling in human

- macrophages independent of interleukin-10," *The Journal of Biological Chemistry*, vol. 284, no. 38, pp. 25569–25575, 2009.
- [176] C. M. van Stijn, J. Kim, A. J. Lusi, G. D. Barish, and R. K. Tangirala, "Macrophage polarization phenotype regulates adiponectin receptor expression and adiponectin anti-inflammatory response," *The FASEB Journal*, vol. 29, no. 2, pp. 636–649, 2015.
- [177] H. A. Periyalil, P. G. Gibson, and L. G. Wood, "Immuno-metabolism in obese asthmatics: are we there yet?" *Nutrients*, vol. 5, no. 9, pp. 3506–3530, 2013.
- [178] O. L. Klein, J. A. Krishnan, S. Glick, and L. J. Smith, "Systematic review of the association between lung function and Type 2 diabetes mellitus," *Diabetic Medicine*, vol. 27, no. 9, pp. 977–987, 2010.
- [179] B. G. J. Dekkers, D. Schaafsma, T. Tran, J. Zaagsma, and H. Meurs, "Insulin-induced laminin expression promotes a hypercontractile airway smooth muscle phenotype," *American Journal of Respiratory Cell and Molecular Biology*, vol. 41, no. 4, pp. 494–504, 2009.
- [180] G. T. McMahon and R. A. Arky, "Inhaled insulin for diabetes mellitus," *The New England Journal of Medicine*, vol. 356, no. 5, pp. 497–502, 2007.
- [181] A. Agrawal, U. Mabalirajan, T. Ahmad, and B. Ghosh, "Emerging interface between metabolic syndrome and asthma," *American Journal of Respiratory Cell and Molecular Biology*, vol. 44, no. 3, pp. 270–275, 2011.
- [182] S. Singh, Y. S. Prakash, A. Linneberg, and A. Agrawal, "Insulin and the lung: connecting asthma and metabolic syndrome," *Journal of Allergy*, vol. 2013, Article ID 627384, 8 pages, 2013.
- [183] P. Dandona, A. Aljada, P. Mohanty et al., "Insulin inhibits intranuclear nuclear factor κ B and stimulates I κ B in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?" *Journal of Clinical Endocrinology and Metabolism*, vol. 86, no. 7, pp. 3257–3265, 2001.
- [184] H. Ghanim, K. Green, S. Abuayseh et al., "Suppressive effect of insulin on the gene expression and plasma concentrations of mediators of asthmatic inflammation," *Journal of Diabetes Research*, vol. 2015, Article ID 202406, 7 pages, 2015.
- [185] M. Cazzola, L. Calzetta, P. Rogliani et al., "High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway," *American Journal of Respiratory Cell and Molecular Biology*, vol. 47, no. 4, pp. 509–516, 2012.
- [186] W. W. Chance, C. Rhee, C. Yilmaz et al., "Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy," *Diabetes Care*, vol. 31, no. 8, pp. 1596–1601, 2008.
- [187] H. O. Koskela, P. H. Salonen, and L. Niskanen, "Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease," *Clinical Respiratory Journal*, vol. 7, no. 4, pp. 382–389, 2013.
- [188] E. Gulcan, I. Bulut, A. Toker, and A. Gulcan, "Evaluation of glucose tolerance status in patients with asthma bronchiale," *Journal of Asthma*, vol. 46, no. 2, pp. 207–209, 2009.
- [189] K. P. Dawson, A. C. Penna, and P. Manglick, "Acute asthma, salbutamol and hyperglycaemia," *Acta Paediatrica*, vol. 84, no. 3, pp. 305–307, 1995.
- [190] P. M. O'Byrne, S. Rennard, H. Gerstein et al., "Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids," *Respiratory Medicine*, vol. 106, no. 11, pp. 1487–1493, 2012.
- [191] A. G. Desai, A. Togias, C. Schechter, B. Fisher, A. Parow, and G. Skloot, "Peripheral airways dysfunction in obesity reflects increased bronchomotor tone," *The Journal of Allergy and Clinical Immunology*, vol. 135, no. 3, pp. 820–822, 2015.
- [192] A. Al-Alwan, J. H. T. Bates, D. G. Chapman et al., "The Non-allergic asthma of obesity: a matter of distal lung compliance," *American Journal of Respiratory and Critical Care Medicine*, vol. 189, no. 12, pp. 1494–1502, 2014.
- [193] J. H. T. Bates and A. E. Dixon, "Potential role of the airway wall in the asthma of obesity," *Journal of Applied Physiology*, vol. 118, no. 1, pp. 36–41, 2015.
- [194] A. Agrawal and Y. S. Prakash, "Obesity, metabolic syndrome, and airway disease: a bioenergetic problem?" *Immunology and Allergy Clinics of North America*, vol. 34, no. 4, pp. 785–796, 2014.
- [195] A. Gardner, A. Johansson, R. Wibom et al., "Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients," *Journal of Affective Disorders*, vol. 76, no. 1–3, pp. 55–68, 2003.
- [196] C. C. Chang, S. H. Jou, T. T. Lin, T. Lai, C. Liu, and Y. Bai, "Mitochondria DNA change and oxidative damage in clinically stable patients with major depressive disorder," *PLoS ONE*, vol. 10, no. 5, Article ID e0125855, 2015.
- [197] M. K. Montgomery and N. Turner, "Mitochondrial dysfunction and insulin resistance: an update," *Endocrine Connections*, vol. 4, no. 1, pp. R1–R15, 2014.
- [198] K. F. Petersen, D. Befroy, S. Dufour et al., "Mitochondrial dysfunction in the elderly: possible role in insulin resistance," *Science*, vol. 300, no. 5622, pp. 1140–1142, 2003.
- [199] U. Mabalirajan, A. K. Dinda, S. Kumar et al., "Mitochondrial structural changes and dysfunction are associated with experimental allergic asthma," *The Journal of Immunology*, vol. 181, no. 5, pp. 3540–3548, 2008.
- [200] L. Aguilera-Aguirre, A. Bacsı, A. Saavedra-Molina, A. Kurosky, S. Sur, and I. Boldogh, "Mitochondrial dysfunction increases allergic airway inflammation," *The Journal of Immunology*, vol. 183, no. 8, pp. 5379–5387, 2009.
- [201] E. K. Larkin, Y.-T. Gao, T. Gebretsadik et al., "New risk factors for adult-onset incident asthma. A nested case-control study of host antioxidant defense," *American Journal of Respiratory and Critical Care Medicine*, vol. 191, no. 1, pp. 45–53, 2015.
- [202] I. Palomo, A. Contreras, L. M. Alarcón et al., "Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome," *Nitric Oxide: Biology and Chemistry*, vol. 24, no. 4, pp. 224–228, 2011.
- [203] J. A. Scott, M. L. North, M. Rafii et al., "Asymmetric dimethylarginine is increased in asthma," *American Journal of Respiratory and Critical Care Medicine*, vol. 184, no. 7, pp. 779–785, 2011.
- [204] K. Krzyzanowska, F. Mittermayer, H.-P. Kopp, M. Wolzt, and G. Scherthaner, "Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women," *The Journal of Clinical Endocrinology and Metabolism*, vol. 89, no. 12, pp. 6277–6281, 2004.
- [205] M. A. Mcevoy, P. Schofield, W. Smith et al., "Serum methylarginines and incident depression in a cohort of older adults," *Journal of Affective Disorders*, vol. 151, no. 2, pp. 493–499, 2013.
- [206] M. L. Selley, "Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression," *Journal of Affective Disorders*, vol. 80, no. 2–3, pp. 249–256, 2004.

- [207] F. Holguin, S. A. A. Comhair, S. L. Hazen et al., "An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype," *American Journal of Respiratory and Critical Care Medicine*, vol. 187, no. 2, pp. 153–159, 2013.
- [208] L. Rochette, J. Lorin, M. Zeller et al., "Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?" *Pharmacology & Therapeutics*, vol. 140, no. 3, pp. 239–257, 2013.
- [209] S. M. Wells and A. Holian, "Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells," *American Journal of Respiratory Cell and Molecular Biology*, vol. 36, no. 5, pp. 520–528, 2007.
- [210] T. Ahmad, U. Mabalirajan, B. Ghosh, and A. Agrawal, "Altered asymmetric dimethyl arginine metabolism in allergically inflamed mouse lungs," *American Journal of Respiratory Cell and Molecular Biology*, vol. 42, no. 1, pp. 3–8, 2010.
- [211] P. Ilmarinen, E. Moilanen, J. S. Erjefält, and H. Kankaanranta, "The polyamine spermine promotes survival and activation of human eosinophils," *The Journal of Allergy and Clinical Immunology*, vol. 136, no. 2, pp. 482.e11–484.e11, 2015.
- [212] M. L. North, H. Grasemann, N. Khanna, M. D. Inman, G. M. Gauvreau, and J. A. Scott, "Increased ornithine-derived polyamines cause airway hyperresponsiveness in a mouse model of asthma," *American Journal of Respiratory Cell and Molecular Biology*, vol. 48, no. 6, pp. 694–702, 2013.
- [213] Z. Bagi, A. Feher, H. Dou, and Z. Broskova, "Selective up-regulation of arginase-1 in coronary arteries of diabetic patients," *Frontiers in Immunology*, vol. 4, article 293, 2013.
- [214] M. L. North, N. Khanna, P. A. Marsden, H. Grasemann, and J. A. Scott, "Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma," *American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 296, no. 6, pp. L911–L920, 2009.
- [215] R. Spanbroek, R. Gräbner, K. Lötzer et al., "Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 3, pp. 1238–1243, 2003.
- [216] F. Cipollone, A. Mezzetti, M. L. Fazia et al., "Association between 5-lipoxygenase expression and plaque instability in humans," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 25, no. 8, pp. 1665–1670, 2005.
- [217] C. Pergola, G. Dodt, A. Rossi et al., "ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 50, pp. 19881–19886, 2008.
- [218] M. Zaitsu, S.-I. Narita, K. C. Lambert et al., "Estradiol activates mast cells via a non-genomic estrogen receptor-alpha and calcium influx." *Molecular Immunology*, vol. 44, no. 8, pp. 1977–1985, 2007.
- [219] H. Kankaanranta, P. Ilmarinen, T. Kankaanranta, and L. E. Tuomisto, "Seinäjoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care," *NPJ Primary Care Respiratory Medicine*, vol. 25, Article ID 15042, 2015.
- [220] P. Kirkham and I. Rahman, "Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy," *Pharmacology & Therapeutics*, vol. 111, no. 2, pp. 476–494, 2006.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

